

Approved



Tanzania
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		763,769		763,769	0	763,769
USAID		222,284,658		222,284,658	31,938,632	254,223,290
DOD	0	37,784,235	0	37,784,235	3,828,160	41,612,395
PC		2,099,990		2,099,990	575,090	2,675,080
HHS/CDC	2,618,750	112,873,206		115,491,956	13,033,510	128,525,466
HHS/HRSA		1,900,000		1,900,000	0	1,900,000
State/AF		300,000		300,000	0	300,000
Total	2,618,750	378,005,858	0	380,624,608	49,375,392	430,000,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC		5,595,472	10,423,121	0			11,514,168	0	27,532,761
HBHC		3,150,693	10,067,795	700,000			5,161,841	0	19,080,329
HKID		37,267	4,156,103	0		150,000	30,375,134	0	34,718,504
HLAB		192,575	2,199,750	0		0	0	0	2,392,325
HMBL			736,500					0	736,500
HMIN			57,612					0	57,612
HTXD		35,766	0				94,288,297	0	94,324,063
HTXS		16,737,090	38,548,796	300,000		0	43,351,120	0	98,937,006
HVAB			0					0	0
HVCT		1,677,366	5,941,292	0			6,824,230	0	14,442,888

Approved



HVMS	763,769	1,315,478	7,063,524		2,086,990		1,615,400	0	12,845,161
HVOP		1,435,843	4,106,188	0	13,000	150,000	7,286,717	0	12,991,748
HVSI		292,327	6,510,697				1,820,688	0	8,623,712
HVTB		812,809	2,973,502	0			3,611,046	0	7,397,357
IDUP			2,768,421	0				0	2,768,421
MTCT		4,575,660	12,189,774	0		0	4,585,164	0	21,350,598
OHSS			3,810,352	900,000			6,808,488	0	11,518,840
PDCS		556,433	851,441				610,756	0	2,018,630
PDTX		1,369,456	3,087,088				4,431,609	0	8,888,153
	763,769	37,784,235	115,491,956	1,900,000	2,099,990	300,000	222,284,658	0	380,624,608



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	18,947,941	0
HKID	34,660,968	0
HVTB	7,300,304	0
PDCS	1,946,979	0
Total Technical Area Planned Funding:	62,856,192	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	1,910,000	0
HVSI	6,889,300	0
OHSS	10,170,018	0
Total Technical Area Planned Funding:	18,969,318	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	27,343,144	0
HMBL	660,000	0
HMIN	0	0
HVCT	14,124,659	0
HVOP	12,854,926	0
IDUP	2,263,593	0
MTCT	21,112,135	0
Total Technical Area Planned	78,358,457	0

Approved



Funding:		
-----------------	--	--

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	94,222,572	0
HTXS	97,655,336	0
PDTX	8,787,928	0
Total Technical Area Planned Funding:	200,665,836	0

Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,478,539
	Number of new ANC and L&D clients	1,556,798
	By: Known positives at entry	20,307
	By: Number of new positives identified	45,757
	Sum of Positives Status disaggregates	66,064
	Required only for DREAMS Countries - By Number of new positives: <15	364
	Required only for DREAMS Countries - By Number of new positives: 15-19	839
	Required only for DREAMS Countries - By Number of new positives: 20-24	1,626
	Required only for DREAMS Countries - By Number of known positives: <15	131
	Required only for DREAMS Countries - By Number of known	318



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	659
	Required only for DREAMS Countries - Denominator: <15	7,170
	Required only for DREAMS Countries - Denominator: <15-19	16,022
	Required only for DREAMS Countries - Denominator: 20-24	33,830
	Required only for DREAMS Countries - Denominator: 25-49	66,156
	Required only for DREAMS Countries - Denominator: 50+	660
	Required only for DREAMS Countries - By Number of known positives: 25-49	1,492
	Required only for DREAMS Countries - By Number of known positives: 50+	10
	Required only for DREAMS Countries - By Number of new positives: 25-49	3,298
	Required only for DREAMS Countries - By Number of new positives: 50+	26
	By Age (DREAMS SNU's ONLY): <15	
	By Age (DREAMS SNU's ONLY): 15-19	
	By Age (DREAMS SNU's ONLY): 20-24	
	By Age (DREAMS SNU's ONLY): 25-49	



	By Age (DREAMS SNU's ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,478,539
	New on ART	43,478
	Already on ART at beginning of current pregnancy	19,305
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	4,931
	Sex: Male	2,382
	Sex: Female	2,549
	Sum of Sex disaggregates	4,931
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	696,449
	By Age: 0-60 days	
	By Age: 2 months - 9 years	
	By Age: 10-14	348,223



	By Age: 15-19	182,442
	By Age: 20-24	54,443
	By Age: 25-29	111,341
	By Age: 30-49	
	By Age: 50+	
	Sum of age disaggregates (Prior to FY15)	585,108
	Sum of age disaggregates (FY15-Current)	696,449
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	696,449
	By circumcision technique: Device-based VMMC	
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PP_PREV_DSD	PP_PREV_DSD Percentage of the	n/a



	target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	159,099
	Total number of people in the target population	279,946
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	



	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	230
	Aggregated Age/sex: 15+ Female	158,869
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	92,796
	Total estimated number of key population in the catchment area	149,234
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	



	<p>By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>10,221</p>
	<p>By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	<p>80,343</p>
	<p>By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual</p>	<p>3,919</p>



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,915
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	17,489
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type:	



	Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	124,825
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	7,196
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	4,874
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received	6,608,245



	their test results during the past 12 months	
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	37,042
	Age/sex: 15-19 Male	15,652
	Age/sex: 20-24 Male	16,020
	Age/sex: 25-49 Male	136,211
	Age/sex: 50+ Male	26,759
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	21,246
	Age/sex: 15-19 Female	34,249
	Age/sex: 20-24 Female	53,322
	Age/sex: 25-49 Female	199,437
	Age/sex: 50+ Female	21,346
	Test Result by Age and Sex: Positive: 10-14 Male	818
	Test Result by Age and Sex: Positive: 15-19 Male	1,029
	Test Result by Age and Sex: Positive: 20-24 Male	1,568
	Test Result by Age and Sex: Positive: 25-49 Male	7,674
	Test Result by Age and Sex: Positive: 50+ Male	1,507
	Test Result by Age and Sex: Positive: 10-14 Female	891
	Test Result by Age and Sex: Positive: 15-19 Female	2,045
	Test Result by Age and Sex: Positive: 20-24 Female	4,017
	Test Result by Age and Sex: Positive: 25-49 Female	16,739
	Test Result by Age and Sex:	1,522



	Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	848,903
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,424,865
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	657,050
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,026,532
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age	



	and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	12,784
	Test Result by Aggregated Age and Sex: Positive 15+ Male	80,177
	Test Result by Aggregated Age and Sex: Positive <15 Female	14,612
	Test Result by Aggregated Age and Sex: Positive 15+ Female	159,364
	Test Result by Age: Positive: <1	408
	Test Result by Age: Positive: 1-9	1,833
	Age/sex: <1	15,970
	Age/sex: 1-9	76,704
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	371,349
	Service Delivery Point (Community): Mobile testing	868,713
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community)	



	by Age: <15 mobile testing	
	Service Delivery Point (Community)	
	by Age: 15+ mobile testing	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Community)	
	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	173,372
	Service Delivery Point (Facility): Outpatient	1,829,605
	Service Delivery Point (Facility): Pediatric	885,261
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	146,951
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	698,063
	Service Delivery Point (Facility): PMTCT	1,616,929
	Service Delivery Point (Facility): TB Clinics	30,605
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by	



	Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of	n/a



	registered new and relapsed TB cases with documented HIV status.	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	39,545
	Total number of registered new and relapsed TB cases, during the reporting period.	39,545
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator:	



	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered	



	new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	24,351
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	15,194
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	



	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	97,709
	Age/Sex: <10 Male	9,846
	Age/Sex: 10-14 Male	12,067
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	5,682
	Age/Sex: 25-49 Male	7,295
	Age/Sex: 50+ Male	830
	Age/Sex: <10 Female	10,791
	Age/Sex: 10-14 Female	16,872
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	6,869
	Age/Sex: 25-49 Female	8,674
	Age/Sex: 50+ Female	1,027
Sum of Age/Sex Disaggregates	49,576	
By type of service: Physical and/or	65,128	



	Emotional Violence (Other Post-GBV Care)	
	By type of service: Sexual Violence (Post-Rape Care)	32,581
	By PEP service provision (related to sexual violence services provided)	4,101
	Age/Sex: 15-19 Female	9,003
	Age/Sex: 15-19 male	8,753
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	692,680
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	77,162
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	77,609
	Sum of Age/Sex disaggregates	154,771
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	5,143
	Required only for DREAMS countries - By service, age and sex: Education Support Female	10,663



	15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	776
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	



	Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female	1,587



	10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	



	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	



	Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	269,647
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	268,262
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	13,551
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	14,413
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of	



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented	7,150



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6,401
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	<p>Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male 15+</p>	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	988,044
	Screened for TB by Age/Sex:<15 Male	31,518
	Screened for TB by Age/Sex: 15+ Male	283,037
	Screened for TB by Age/Sex:<15 Female	34,732
	Screened for TB by Age/Sex: 15+ Female	638,757
	Screen Result: Screened Positive for TB	15,542
	TB Positive by Age/Sex: <15 Male	



	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	15,542
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	13,682
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,628
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	232
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	47,418
	By infants who received their first virologic HIV test between 2 and 12 months of age	15,397
	Sum of Infant Age disaggregates	62,815
	By infants with a positive virologic test result within 12 months of birth	



	Number of infants with a positive virological test result within 2 months of birth	1,134
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	442
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,040,081
	Age/Sex: 15-19 Male	2,768
	Age/Sex: 15-19 Female	5,961
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	29,956
	Aggregated Age/Sex: 15+ Male	243,087
	Aggregated Age/Sex: <15 Female	28,458
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	592,637
	Sum of Aggregated Age/Sex <15	58,414
	Sum of Aggregated Age/Sex 15+	835,724
	Sum of Aggregated Age/Sex disaggregates	894,138
	Age/Sex: <1	174
Age/Sex: <1-9	5,742	



	Age/Sex: 10-14 Male	1,480
	Age/Sex: 10-14 Female	1,362
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	1,464
	Age/Sex: 25-49 Male	24,211
	Age/Sex: 50+ Male	6,376
	Age/Sex: 20-24 Female	15,341
	Age/Sex: 25-49 Female	73,307
	Age/Sex: 50+ Female	7,757
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	319,623
	By Age/Sex: <1	174
	By Age/Sex: 1-9	1,755
	By Age/Sex: 10-14 Male	392
	By Age/Sex: 15-19 Male	1,118
	By Age/Sex: 20-24 Male	518
	By Age/Sex: 25-49 Male	10,134
	By Age/Sex: 50+ Male	2,504
	By Age/Sex: 10-14 Female	541
	By Age/Sex: 15-19 Female	3,060
	By Age/Sex: 20-24 Female	5,758
	By Age/Sex: 25-49 Female	25,686
	By Age/Sex: 50+ Female	3,066
	Sum of Age/Sex disaggregates	52,777
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	9,632



	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	70,232
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	10,229
	Aggregated Grouping by Age/Sex: 15+ Female	174,824
	Sum of Aggregated Age/Sex disaggregates	264,917
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	635,059
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	704,431
	Numerator: Indication: Routine	288,484



	Numerator: Indication: Targeted	346,575
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication:	



	<1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by	



	Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	319,624
	Denominator: Indication: Targeted	384,807
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by	



	Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex	



	by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	21,537
	Numerator Aggregated Age/Sex: 15+ Male	170,984
	Numerator Aggregated Age/Sex: <15 Female	21,725
	Numerator Aggregated Age/Sex: 15+ Female	420,813
	Denominator Aggregated Age/Sex: <15 Male	23,748
	Denominator Aggregated Age/Sex: 15+ Male	189,714
	Denominator Aggregated Age/Sex: <15 Female	23,995
	Denominator Aggregated Age/Sex: 15+ Female	466,974
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	110,731



	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	147,827
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	46
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	442
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	89
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	313
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	161
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,722
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	679



	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	101
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	787
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,518
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,280
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	806
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have	580



	died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	117
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	411
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	218
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,627
	Age/Sex: 50+ Male (Denominator: Total number of adults and children	904



	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	141
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,041
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,011
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	8,367



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,072
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status:	



	Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,139
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27,879
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,476
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60,293
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,566
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated	37,234



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,028
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	80,446
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1,059
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1,186
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful	973



	passing criteria in this PT program	
	CD4: Number of laboratories that perform this testing	473
	CD4: Number of laboratories that participate in this PT program	327
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	214
	Early infant diagnostics: Number of laboratories that perform this testing	31
	Early infant diagnostics: Number of laboratories that participate in this PT program	32
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	35
	HIV viral load: Number of laboratories that perform this testing	6
	HIV viral load: Number of laboratories that participate in this PT program	19
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	7
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	471
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	370
	TB diagnostics (AFB microscopy):	366



	Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	49
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	41
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	38
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	3
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	3
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	7
	CD4: Number of laboratories that participate in this PT program	16
	CD4: Number of laboratories that	18



	perform this testing	
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	Early infant diagnostics: Number of laboratories that participate in this PT program	
	Early infant diagnostics: Number of laboratories that perform this testing	
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	708
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	650
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	960
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	HIV viral load: Number of laboratories that participate in this PT program	
	HIV viral load: Number of laboratories that perform this testing	
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	31



	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	39
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	71
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	5,559
	By Graduates: Doctors	187
	By Graduates: Nurses	4,169
	By Graduates: Midwives	564



	By Graduates: Social service workers	0
	By Graduates: Laboratory professionals	251
	By Graduates: Other	388
	Sum of Graduates disaggreagtes	5,559
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	
	Number of HIV Test Kits purchased	79,203
	Number of HIV CD4 Reagents purchased	42,838
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	830,206
	Number of HIV ARVs purchased	657,294
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	2,722,348
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	1,223,025
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	
	Condoms: Dollars planned (COP)/ spent (Actual)	1,006,557
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7234	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	0
7241	PharmAccess	NGO	U.S. Department of Defense	GHP-State	4,440,774
7242	Central Contraceptive Procurement	Private Contractor	U.S. Agency for International Development	GHP-State	0
9616	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9618	Touch Foundation	NGO	U.S. Agency for International Development	GHP-State	900,000
9639	Bugando Medical Centre	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9681	National Tuberculosis and Leprosy Control	Host Country Government Agency	U.S. Department of Health and Human	GHP-State	0



	Program		Services/Centers for Disease Control and Prevention		
10092	Tanzania Youth Alliance	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10809	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10970	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	300,000
11528	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	13,000
12200	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12227	Population Services International	NGO	U.S. Agency for International Development	GHP-State	0
12234	Tanzania Commission for AIDS	Host Country Government Agency	U.S. Department of Health and Human	GHP-State	0



			Services/Centers for Disease Control and Prevention		
12238	Tanzania Interfaith Partnerships	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12245	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12246	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12247	Harvard University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12728	Research Triangle International	Private Contractor	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease Control and Prevention		
12738	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
12810	Pact, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	0
12818	Catholic Relief Services	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12823	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12827	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Agency for International Development	GHP-State	0
12829	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12854	Vodafone Foundation	NGO	U.S. Agency for International	GHP-State	0



			Development		
12861	Africare	NGO	U.S. Agency for International Development	GHP-State	0
12906	Christian Social Services Commission	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12907	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
13013	American Association of Blood Banks	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13301	World Education	NGO	U.S. Agency for International Development	GHP-State	0
13351	Northrup Grumman	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	750,000
13355	Ministry of Health and Social Welfare, Tanzania - Zanzibar AIDS	Host Country Government Agency	U.S. Department of Health and Human Services/Centers	GHP-State	0



	Control Program		for Disease Control and Prevention		
13359	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
13518	TBD	TBD	Redacted	Redacted	Redacted
13553	Balm in Gilead	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13554	Foundation for Innovative New Diagnostics	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13555	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13774	International Youth Foundation	NGO	U.S. Agency for International Development	GHP-State	0
14536	Ariel Glaser	NGO	U.S. Department	GHP-State	0



	Pediatric AIDS Healthcare Initiative		of Health and Human Services/Centers for Disease Control and Prevention		
14544	Tanzania Red Cross Society	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,913,421
14551	Kagera RHMT	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14552	Mtwara RHMT	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14553	Mwanza RHMT	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14554	Pwani RHMT	Host Country Government	U.S. Department of Health and	GHP-State	0



		Agency	Human Services/Centers for Disease Control and Prevention		
14555	Tanga RHMT	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14556	Tanzania Youth Alliance	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,310,712
14560	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	150,000
14573	National AIDS Control Program Tanzania	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	524,500
14653	African Medical and Research Foundation,	NGO	U.S. Department of Health and Human	GHP-State	360,000



	Tanzania		Services/Centers for Disease Control and Prevention		
14680	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	0
14685	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
14689	Pastoral Activities & Services for People with AIDS	FBO	U.S. Agency for International Development	GHP-State	0
14690	Selian Lutheran Hospital, Tanzania	FBO	U.S. Agency for International Development	GHP-State	0
14691	National Council for People Living with HIV/AIDS Tanzania	NGO	U.S. Agency for International Development	GHP-State	2,489,128
14692	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	1,549,759
14693	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	5,600,000
14694	TBD	TBD	Redacted	Redacted	Redacted
14698	United Nations Children's Fund	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	200,000
16397	Deloitte Consulting Limited	Private Contractor	U.S. Agency for International Development	GHP-State	0
16569	University of North Carolina	University	U.S. Agency for International	GHP-State	2,325,000



			Development		
16763	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	31,418,623
16784	JHPIEGO	University	U.S. Agency for International Development	GHP-State	11,756,220
16787	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	8,860,864
16792	TBD	TBD	Redacted	Redacted	Redacted
16820	Engender Health	Private Contractor	U.S. Agency for International Development	GHP-State	0
16874	Tanzania Health Promotion Support (THPS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,218,304
16876	T-MARC Tanzania	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16877	Christian Council of Tanzania	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,929,142
16878	African Medical	NGO	U.S. Department	GHP-State	0



	and Research Foundation, Tanzania		of Health and Human Services/Centers for Disease Control and Prevention		
16884	Drug Control Commission	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16885	Muhimbili University College of Health Sciences	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,196,465
16886	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	170,000
16887	Ministry of Health and Social Welfare, Tanzania	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	390,000
16891	Clinical and Laboratory	NGO	U.S. Department of Health and	GHP-State	250,000



	Standards Institute		Human Services/Centers for Disease Control and Prevention		
16892	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	225,000
16899	Management development for Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	871,300
17082	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	3,950,000
17102	Muhimbili University College of Health Sciences	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
17103	Baylor College of Medicine International Pediatric AIDS Initiative/Tanzania	University	U.S. Agency for International Development	GHP-State	1,945,521
17151	FHI 360	NGO	U.S. Agency for International	GHP-State	0



			Development		
17292	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	450,000
17293	Management development for Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	18,958,980
17294	Ministry of Health and Social Welfare, Tanzania	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	190,000
17295	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17296	Cardno Emerging Markets	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,325,000



17300	National Institute for Medical Research	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
17304	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
17305	American International Health Alliance	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	1,900,000
17316	United Nations Children's Fund	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,050,000
17343	Ministry of Health and Social Welfare, Tanzania	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	120,000
17357	Population	NGO	U.S. Agency for	GHP-State	1,242,000



	Council		International Development		
17358	TBD	TBD	Redacted	Redacted	Redacted
17409	JHPIEGO	University	U.S. Agency for International Development	GHP-State	1,780,000
17416	TBD	TBD	Redacted	Redacted	Redacted
17420	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	1,348,105
17970	TBD	TBD	Redacted	Redacted	Redacted
17975	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,079,144
17982	ICF Macro	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,000
17983	TBD	TBD	Redacted	Redacted	Redacted
17984	TBD	TBD	Redacted	Redacted	Redacted
17985	TBD	TBD	Redacted	Redacted	Redacted
17986	Ariel Glaser Pediatric AIDS Healthcare Initiative	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	25,873,992



17987	TBD	TBD	Redacted	Redacted	Redacted
17988	TBD	TBD	Redacted	Redacted	Redacted
17990	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,200,000
17991	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,918,868
17992	TBD	TBD	Redacted	Redacted	Redacted
17993	Tanzania Commission for AIDS	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
18056	TBD	TBD	Redacted	Redacted	Redacted
18057	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0
18058	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	350,000
18059	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	0
18060	Elizabeth Glaser	NGO	U.S. Agency for	GHP-State	8,907,563



	Pediatric AIDS Foundation		International Development		
18061	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-State	650,000
18072	New Partner	TBD	U.S. Agency for International Development	GHP-State	7,000,000
18130	Research Triangle International	Private Contractor	U.S. Department of Defense	GHP-State	250,000
18131	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	10,240,791
18170	TBD	TBD	Redacted	Redacted	Redacted
18171	TBD	TBD	Redacted	Redacted	Redacted
18197	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	0
18198	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	115,402,195
18199	Chemonics International	Private Contractor	U.S. Agency for International Development	GHP-State	200,000
18200	TBD	TBD	Redacted	Redacted	Redacted
18201	TBD	TBD	Redacted	Redacted	Redacted
18202	New Partner	TBD	U.S. Agency for International Development	GHP-State	0
18237	Deloitte Consulting	Private Contractor	U.S. Agency for International	GHP-State	13,697,663



	Limited		Development		
18238	TBD	TBD	Redacted	Redacted	Redacted
18239	TBD	TBD	Redacted	Redacted	Redacted
18243	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
18258	Public Health Informatics Institute	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	150,000



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 7234	Mechanism Name: Global Health Supply Chain Program (SCMS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	7234		
Mechanism Name:	Global Health Supply Chain Program (SCMS)		
Prime Partner Name:	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7241	Mechanism Name: PAI-DOD
---------------------------	--------------------------------



Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: PharmAccess	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,440,774	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,440,774	
Funding Source	Funding Amount
GHP-State	4,440,774

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 7241			
Mechanism Name: PAI-DOD			
Prime Partner Name: PharmAccess			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	464,431	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	37,267	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	87,985	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	17,364	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	500,172	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	249,067	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	36,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	251,449	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,654,356	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	142,683	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,183
PMTCT_ART_DSD	New on ART	554
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	241
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,183
PMTCT_STAT_DSD	Number of new ANC and L&D clients	15,306
PMTCT_STAT_DSD	By: Known positives at entry	254



PMTCT_STAT_DSD	By: Number of new positives identified	583
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	837
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	7
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	15
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	3
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	8
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	43
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	116
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	284
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	712
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	10
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	18
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	34
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,832
VMMC_CIRC_DSD	By Age: 10-14	6,416
VMMC_CIRC_DSD	By Age: 15-19	3,917
VMMC_CIRC_DSD	By Age: 20-24	864



VMMC_CIRC_DSD	By Age: 25-29	1,635
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	11,197
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	12,832
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	12,832
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,000
PP_PREV_DSD	Total number of people in the target population	19,922
PP_PREV_DSD	Aggregated Age/sex: <15 Female	230
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	770
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	106,471
HTC_TST_DSD	Age/sex: 10-14 Male	574
HTC_TST_DSD	Age/sex: 15-19 Male	455
HTC_TST_DSD	Age/sex: 20-24 Male	394
HTC_TST_DSD	Age/sex: 25-49 Male	1,305
HTC_TST_DSD	Age/sex: 50+ Male	574
HTC_TST_DSD	Age/sex: 10-14 Female	319
HTC_TST_DSD	Age/sex: 15-19 Female	501
HTC_TST_DSD	Age/sex: 20-24 Female	746
HTC_TST_DSD	Age/sex: 25-49 Female	2,771
HTC_TST_DSD	Age/sex: 50+ Female	610
HTC_TST_DSD	Sum of Age/Sex disaggregates	8,249
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	28
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	22
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	26
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	96
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	45
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	32
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	43
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	91



HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	210
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	52
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	16,352
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,489
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	11,764
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	45,114
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	28,116
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	68,603
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	96,719
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	362
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,875
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	252
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,891
HTC_TST_DSD	Test Result by Age: Positive: <1	3
HTC_TST_DSD	Test Result by Age: Positive: 1-9	39
HTC_TST_DSD	Age/sex: <1	262
HTC_TST_DSD	Age/sex: 1-9	1,241
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	7,582
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	17,946
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	3,036
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	32,185
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	15,091
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	2,718
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	12,832



HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	15,081
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,050
OVC_SERV_DSD	Age/Sex: 18+ Male	57
OVC_SERV_DSD	Age/Sex: 18+ Female	90
OVC_SERV_DSD	Sum of Age/Sex disaggregates	147
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	360
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	543
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	22,626
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	613
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	6,050
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	637
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	15,326
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	366
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	366
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	320
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	37
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	9
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	666
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	127
PMTCT_EID_DSD	Sum of Infant Age disaggregates	793
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	13
PMTCT_EID_DSD	Number of infants with a positive virological test result	7



	within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	23,815
TX_CURR_DSD	Age/Sex: 15-19 Male	38
TX_CURR_DSD	Age/Sex: 15-19 Female	71
TX_CURR_DSD	Sum of age/sex disaggregates	109
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	691
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	5,597
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	655
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	15,723
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,346
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	21,320
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	22,666
TX_CURR_DSD	Age/Sex: <1	2
TX_CURR_DSD	Age/Sex: <1-9	46
TX_CURR_DSD	Age/Sex: 10-14 Male	14
TX_CURR_DSD	Age/Sex: 10-14 Female	11
TX_CURR_DSD	Age/Sex: 20-24 Male	9
TX_CURR_DSD	Age/Sex: 25-49 Male	167
TX_CURR_DSD	Age/Sex: 50+ Male	48
TX_CURR_DSD	Age/Sex: 20-24 Female	121
TX_CURR_DSD	Age/Sex: 25-49 Female	564
TX_CURR_DSD	Age/Sex: 50+ Female	58
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,970
TX_NEW_DSD	By Age/Sex: <1	2
TX_NEW_DSD	By Age/Sex: 1-9	15
TX_NEW_DSD	By Age/Sex: 10-14 Male	3
TX_NEW_DSD	By Age/Sex: 15-19 Male	20
TX_NEW_DSD	By Age/Sex: 20-24 Male	4
TX_NEW_DSD	By Age/Sex: 25-49 Male	87
TX_NEW_DSD	By Age/Sex: 50+ Male	23



TX_NEW_DSD	By Age/Sex: 10-14 Female	4
TX_NEW_DSD	By Age/Sex: 15-19 Female	39
TX_NEW_DSD	By Age/Sex: 20-24 Female	51
TX_NEW_DSD	By Age/Sex: 25-49 Female	221
TX_NEW_DSD	By Age/Sex: 50+ Female	25
TX_NEW_DSD	Sum of Age/Sex disaggregates	477
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	245
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,584
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	227
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,420
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,476
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	12,834
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14,244
TX_PVLS_DSD	Numerator: Indication: Routine	6,281
TX_PVLS_DSD	Numerator: Indication: Targeted	6,553
TX_PVLS_DSD	Denominator: Indication: Routine	6,970
TX_PVLS_DSD	Denominator: Indication: Targeted	7,274
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	433
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	3,291
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	413
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	8,697
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	478
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	3,656
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	454
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	9,656
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,956
TX_RET_DSD	Total number of adults and children who initiated ART	2,623



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	72
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	2



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	42
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	1



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	97
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	70
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	492
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,152
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total	98



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	662
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	105
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,533
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	49
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	49
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	46
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	22
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	22
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	22
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	26
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	26



LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	29
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	25
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	25
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	25
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	5
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	5
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	5

Implementing Mechanism Details

Mechanism ID: 7242	Mechanism Name: Condom Procurement
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Central Contraceptive Procurement	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 7242			
Mechanism Name: Condom Procurement			
Prime Partner Name: Central Contraceptive Procurement			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9616	Mechanism Name: IHI-MC
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 9616			
Mechanism Name: IHI-MC			
Prime Partner Name: IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9618	Mechanism Name: Touch Foundation- PPP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Touch Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 900,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 900,000	
Funding Source	Funding Amount
GHP-State	900,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9618			
Mechanism Name: Touch Foundation- PPP			
Prime Partner Name: Touch Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	900,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	708
HRH_PRE	By Graduates: Doctors	187
HRH_PRE	By Graduates: Nurses	130
HRH_PRE	By Graduates: Laboratory professionals	247
HRH_PRE	By Graduates: Other	144
HRH_PRE	Sum of Graduates disaggreagtes	708

Implementing Mechanism Details

Mechanism ID: 9639	Mechanism Name: BMC
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Bugando Medical Centre	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9639			
Mechanism Name: BMC			
Prime Partner Name: Bugando Medical Centre			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9681	Mechanism Name: Single eligibility FOA
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Tuberculosis and Leprosy Control Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 9681			
Mechanism Name: Single eligibility FOA			
Prime Partner Name: National Tuberculosis and Leprosy Control Program			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10092	Mechanism Name: Helpline & Youth
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tanzania Youth Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 10092			
Mechanism Name: Helpline & Youth			
Prime Partner Name: Tanzania Youth Alliance			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10809	Mechanism Name: AFENET Lab
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10809		
Mechanism Name:	AFENET Lab		
Prime Partner Name:	African Field Epidemiology Network		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10970	Mechanism Name: Ambassador's HIV/AIDS Relief Fund
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount
GHP-State	300,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 10970			
Mechanism Name: Ambassador's HIV/AIDS Relief Fund			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11528	Mechanism Name: U.S. Peace Corps
----------------------------	---

Approved



Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 13,000	
Applied Pipeline Amount: 100,000	
Total All Funding Sources and Applied Pipeline Amount: 113,000	
Funding Source	Funding Amount
GHP-State	13,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11528			
Mechanism Name: U.S. Peace Corps			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	13,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12200	Mechanism Name: UNAIDS-M&E TA
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12200		
Mechanism Name:	UNAIDS-M&E TA		
Prime Partner Name:	UNAIDS - Joint United Nations Programme on HIV/AIDS		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 12227	Mechanism Name: Tanzania Social Marketing Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12227		
Mechanism Name:	Tanzania Social Marketing Program		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12234	Mechanism Name: TACAIDS-M&E
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tanzania Commission for AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12234		
Mechanism Name:	TACAIDS-M&E		
Prime Partner Name:	Tanzania Commission for AIDS		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	HTXS	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12238	Mechanism Name: FBO Networks
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tanzania Interfaith Partnerships	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12238		
Mechanism Name:	FBO Networks		
Prime Partner Name:	Tanzania Interfaith Partnerships		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12245	Mechanism Name: UCSF
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	12245		
Mechanism Name:	UCSF		
Prime Partner Name:	University of California at San Francisco		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	19
HRH_PRE	By Graduates: Other	19
HRH_PRE	Sum of Graduates disaggreagtes	19

Implementing Mechanism Details

Mechanism ID: 12246	Mechanism Name: Columbia
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12246			
Mechanism Name: Columbia			
Prime Partner Name: Columbia University Mailman School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12247	Mechanism Name: Harvard
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Harvard University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12247		
Mechanism Name:	Harvard		
Prime Partner Name:	Harvard University School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12728	Mechanism Name: Data warehouse
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12728			
Mechanism Name: Data warehouse			
Prime Partner Name: Research Triangle International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 12738	Mechanism Name: Pamoja Tuwalee
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12738			
Mechanism Name: Pamoja Tuwalee			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Approved



Mechanism ID: 12810	Mechanism Name: Pamoja Tuwalee
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12810		
Mechanism Name:	Pamoja Tuwalee		
Prime Partner Name:	Pact, Inc.		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12818	Mechanism Name: CRS Follow on
----------------------------	--------------------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12818			
Mechanism Name: CRS Follow on			
Prime Partner Name: Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12823	Mechanism Name: EGPAF Follow on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 12823			
Mechanism Name: EGPAF Follow on			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12827	Mechanism Name: Tanzania Capacity and Communication Project (TCCP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12827		
Mechanism Name:	Tanzania Capacity and Communication Project (TCCP)		
Prime Partner Name:	Johns Hopkins University Bloomberg School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12829	Mechanism Name: IPC TA MOHSW
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12829			
Mechanism Name: IPC TA MOHSW			
Prime Partner Name: JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12854	Mechanism Name: Vodafone Foundation PPP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Vodafone Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12854			
Mechanism Name: Vodafone Foundation PPP			
Prime Partner Name: Vodafone Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	PDTX	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12861	Mechanism Name: Pamoja Tuwalee - Africare
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Africare	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12861		
Mechanism Name:	Pamoja Tuwalee - Africare		
Prime Partner Name:	Africare		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12906	Mechanism Name: CSSC
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Social Services Commission	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12906		
Mechanism Name:	CSSC		
Prime Partner Name:	Christian Social Services Commission		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12907	Mechanism Name: RPSO
Funding Agency: State/AF	Procurement Type: Contract
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12907			
Mechanism Name: RPSO			
Prime Partner Name: Regional Procurement Support Office/Frankfurt			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13013	Mechanism Name: Blood Technical Assistance
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Association of Blood Banks	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13013		
Mechanism Name:	Blood Technical Assistance		
Prime Partner Name:	American Association of Blood Banks		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13301	Mechanism Name: Pamoja Tuwalee
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Education	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13301			
Mechanism Name: Pamoja Tuwalee			
Prime Partner Name: World Education			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13351	Mechanism Name: PROMIS
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: Northrup Grumman	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 750,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 750,000	
Funding Source	Funding Amount
GHP-State	750,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13351			
Mechanism Name: PROMIS			
Prime Partner Name: Northrup Grumman			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	750,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13355	Mechanism Name: ZACP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Welfare, Tanzania - Zanzibar AIDS Control Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13355		
Mechanism Name:	ZACP		
Prime Partner Name:	Ministry of Health and Social Welfare, Tanzania - Zanzibar AIDS Control Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13359	Mechanism Name: I-TECH
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 13359			
Mechanism Name: I-TECH			
Prime Partner Name: University of Washington			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	HTXS	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13518	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 13553	Mechanism Name: FBO TA Provider
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Balm in Gilead	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 13553			
Mechanism Name: FBO TA Provider			
Prime Partner Name: Balm in Gilead			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13554	Mechanism Name: FIND
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Innovative New Diagnostics	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13554



Mechanism Name:	FIND		
Prime Partner Name:	Foundation for Innovative New Diagnostics		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13555	Mechanism Name: FELTP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	13555		
Mechanism Name:	FELTP		
Prime Partner Name:	African Field Epidemiology Network		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13774	Mechanism Name: Tanzania Youth Scholars
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: International Youth Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 13774			
Mechanism Name: Tanzania Youth Scholars			
Prime Partner Name: International Youth Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14536		Mechanism Name: AGPAHI	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: Ariel Glaser Pediatric AIDS Healthcare Initiative			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 14536			
Mechanism Name: AGPAHI			
Prime Partner Name: Ariel Glaser Pediatric AIDS Healthcare Initiative			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14544	Mechanism Name: TRCS
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tanzania Red Cross Society	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 5,913,421	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,913,421	
Funding Source	Funding Amount
GHP-State	5,913,421

Cross-Cutting Budget Attribution(s)

Human Resources for Health	1,000,000
Economic Strengthening	500,000
Gender: GBV	448,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	110,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Equity in HIV prevention, care, treatment and support

Budget Code Information



Mechanism ID: 14544			
Mechanism Name: TRCS			
Prime Partner Name: Tanzania Red Cross Society			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,557,473	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	3,355,948	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	66,682
OVC_SERV_DSD	Age/Sex: 18+ Male	134
OVC_SERV_DSD	Age/Sex: 18+ Female	135
OVC_SERV_DSD	Sum of Age/Sex disaggregates	269
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,587
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	776
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,587
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	33,530
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	32,883

Implementing Mechanism Details

Mechanism ID: 14551	Mechanism Name: Kagera
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kagera RHMT	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14551		
Mechanism Name:	Kagera		
Prime Partner Name:	Kagera RHMT		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 14552	Mechanism Name: Mtwara
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mtwara RHMT	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14552			
Mechanism Name: Mtwara			
Prime Partner Name: Mtwara RHMT			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14553	Mechanism Name: Mwanza
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mwanza RHMT	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14553		
Mechanism Name:	Mwanza		
Prime Partner Name:	Mwanza RHMT		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14554	Mechanism Name: Pwani
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Pwani RHMT	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14554		
Mechanism Name:	Pwani		
Prime Partner Name:	Pwani RHMT		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	HTXS	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14555	Mechanism Name: Tanga
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tanga RHMT	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14555			
Mechanism Name: Tanga			
Prime Partner Name: Tanga RHMT			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14556	Mechanism Name: Diffusion of Effective Behavioral Interventions
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tanzania Youth Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,310,712	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,310,712	
Funding Source	Funding Amount
GHP-State	1,310,712

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14556
Mechanism Name:	Diffusion of Effective Behavioral Interventions
Prime Partner Name:	Tanzania Youth Alliance



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,160,712	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	150,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	22,459
PP_PREV_DSD	Total number of people in the target population	50,144
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	22,459
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	9,626
KP_PREV_DSD	Total estimated number of key population in the catchment area	21,294
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,626
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	21,294
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	104,736
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	8,491



	ONLY: <15 Male	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,096
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	25,071
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	53,078
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	33,562
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	71,174
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	104,736
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	167
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,555
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	505
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,667
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	29,569
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	75,171

Implementing Mechanism Details

Mechanism ID: 14560	Mechanism Name: ASLM - (GH000710)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount



GHP-State	150,000
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14560		
Mechanism Name:	ASLM - (GH000710)		
Prime Partner Name:	African Society for Laboratory Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14573	Mechanism Name: NACP Follow-on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National AIDS Control Program Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 524,500	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 524,500	
Funding Source	Funding Amount



GHP-State	524,500
-----------	---------

Cross-Cutting Budget Attribution(s)

Human Resources for Health	400,000
Key Populations: MSM and TG	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	150,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation



Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 14573			
Mechanism Name: NACP Follow-on			
Prime Partner Name: National AIDS Control Program Tanzania			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	37,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	60,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	112,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	200,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	15,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14653	Mechanism Name: AMREF- LAB - (GH000641)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation, Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 360,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 360,000	
Funding Source	Funding Amount
GHP-State	360,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14653		
Mechanism Name:	AMREF- LAB - (GH000641)		
Prime Partner Name:	African Medical and Research Foundation, Tanzania		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	360,000	0
------------------------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14680	Mechanism Name: LIFE Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14680		
Mechanism Name:	LIFE Program		
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Care	PDCS	0	0
------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14685	Mechanism Name: FANTA III
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14685			
Mechanism Name: FANTA III			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14689	Mechanism Name: Pastoral Activities & Services for People with AIDS
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pastoral Activities & Services for People with AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14689



Mechanism Name: Pastoral Activities & Services for People with AIDS			
Prime Partner Name: Pastoral Activities & Services for People with AIDS			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14690	Mechanism Name: Selian Lutheran Hospital Follow-on
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Selian Lutheran Hospital, Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14690



Mechanism Name:	Selian Lutheran Hospital Follow-on		
Prime Partner Name:	Selian Lutheran Hospital, Tanzania		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14691	Mechanism Name: Citizens engaging in government oversight (CEGO) (CSO Grants: Advocacy)
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: National Council for People Living with HIV/AIDS Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,489,128	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,489,128	
Funding Source	Funding Amount
GHP-State	2,489,128

Cross-Cutting Budget Attribution(s)

Food and Nutrition: Commodities	100,000
Economic Strengthening	200,000
Gender: Gender Equality	300,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms



Sub Area:	Collection and Use of Gender-related Strategic Information
Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	239,493
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Monitoring and Evaluation
Water	250,000

Budget Code Information

Mechanism ID:	14691		
Mechanism Name:	Citizens engaging in government oversight (CEGO) (CSO Grants: Advocacy)		
Prime Partner Name:	National Council for People Living with HIV/AIDS Tanzania		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,489,128	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14692	Mechanism Name: Community Health and Social Systems Strengthening Program (CHSSP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,549,759	
Applied Pipeline Amount: 500,000	
Total All Funding Sources and Applied Pipeline Amount: 2,049,759	
Funding Source	Funding Amount
GHP-State	1,549,759

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14692			
Mechanism Name: Community Health and Social Systems Strengthening Program (CHSSP)			
Prime Partner Name: John Snow Inc (JSI)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,549,759	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14693	Mechanism Name: Public Sector System
----------------------------	---



	Strengthening (PS3)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 5,600,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,600,000	
Funding Source	Funding Amount
GHP-State	5,600,000

Cross-Cutting Budget Attribution(s)

Economic Strengthening	100,000
Education	100,000
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Human Resources for Health	1,000,000
Water	100,000

Budget Code Information

Mechanism ID: 14693			
Mechanism Name: Public Sector System Strengthening (PS3)			
Prime Partner Name: Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	2,700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,950,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14694	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 14698	Mechanism Name: National Capacity Building
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount



GHP-State	200,000
-----------	---------

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms

Budget Code Information

Mechanism ID: 14698			
Mechanism Name: National Capacity Building			
Prime Partner Name: United Nations Children's Fund			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16397	Mechanism Name: Tunajali II
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Deloitte Consulting Limited	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16397			
Mechanism Name: Tunajali II			
Prime Partner Name: Deloitte Consulting Limited			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16569	Mechanism Name: MEASURE Associate Award
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 2,325,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,325,000	
Funding Source	Funding Amount
GHP-State	2,325,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	691,509
----------------------------	---------

Budget Code Information

Mechanism ID: 16569			
Mechanism Name: MEASURE Associate Award			
Prime Partner Name: University of North Carolina			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,525,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	800,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 16763	Mechanism Name: HJFMRI
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 31,418,623	
Applied Pipeline Amount: 2,529,998	
Total All Funding Sources and Applied Pipeline Amount: 33,948,621	
Funding Source	Funding Amount
GHP-State	31,418,623

Cross-Cutting Budget Attribution(s)

Gender: GBV	413,493
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	50,000
Motor Vehicles: Purchased	480,000

Budget Code Information

Mechanism ID:	16763
Mechanism Name:	HJFMRI
Prime Partner Name:	Henry Jackson Foundation



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,669,331	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	724,824	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	530,604	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	170,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	5,078,369	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,366,218	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,382,912	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	4,307,280	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	13,982,065	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,207,020	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	241,833
PMTCT_ART_DSD	New on ART	9,290
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,194
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	241,833
PMTCT_STAT_DSD	Number of new ANC and L&D clients	254,579
PMTCT_STAT_DSD	By: Known positives at entry	4,420
PMTCT_STAT_DSD	By: Number of new positives identified	9,768
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	14,188
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	240
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	444
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	681
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	93
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	178
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	267
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	3,358
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	6,215
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	11,017
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	15,486
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	397

	known positives: 25-49	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	955
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	195,206
VMMC_CIRC_DSD	By Age: 10-14	97,600
VMMC_CIRC_DSD	By Age: 15-19	45,530
VMMC_CIRC_DSD	By Age: 20-24	22,649
VMMC_CIRC_DSD	By Age: 25-29	29,427
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	165,779
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	195,206
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	195,206
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	24,960
PP_PREV_DSD	Total number of people in the target population	30,561
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	24,960
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	7,198
KP_PREV_DSD	Total estimated number of key population in the catchment area	9,053
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	910
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,288



KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	928
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	8,125
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,015,927
HTC_TST_DSD	Age/sex: 10-14 Male	12,770
HTC_TST_DSD	Age/sex: 15-19 Male	4,338
HTC_TST_DSD	Age/sex: 20-24 Male	3,058
HTC_TST_DSD	Age/sex: 25-49 Male	30,486
HTC_TST_DSD	Age/sex: 50+ Male	6,061
HTC_TST_DSD	Age/sex: 10-14 Female	1,081
HTC_TST_DSD	Age/sex: 15-19 Female	6,404
HTC_TST_DSD	Age/sex: 20-24 Female	8,598
HTC_TST_DSD	Age/sex: 25-49 Female	34,054
HTC_TST_DSD	Age/sex: 50+ Female	4,836
HTC_TST_DSD	Sum of Age/Sex disaggregates	111,686
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	163
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	251
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	271
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,724
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	323
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	67
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	603
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	829
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	3,190
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	453
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	145,970



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	224,686
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	77,896
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	430,820
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	223,866
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	655,506
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	879,372
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	2,906
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	16,340
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2,204
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	25,117
HTC_TST_DSD	Test Result by Age: Positive: <1	49
HTC_TST_DSD	Test Result by Age: Positive: 1-9	472
HTC_TST_DSD	Age/sex: <1	3,038
HTC_TST_DSD	Age/sex: 1-9	21,831
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	63,311
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	81,008
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	25,593
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	264,568
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	112,281
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	23,053
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	195,206
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	250,907
GEND_GBV_DSD	Number of people receiving post-GBV care	18,350
GEND_GBV_DSD	Age/Sex: <10 Male	1,848
GEND_GBV_DSD	Age/Sex: 10-14 Male	2,265



GEND_GBV_DSD	Age/Sex: 20-24 Male	1,064
GEND_GBV_DSD	Age/Sex: 25-49 Male	1,372
GEND_GBV_DSD	Age/Sex: 50+ Male	159
GEND_GBV_DSD	Age/Sex: <10 Female	2,032
GEND_GBV_DSD	Age/Sex: 10-14 Female	3,179
GEND_GBV_DSD	Age/Sex: 20-24 Female	1,289
GEND_GBV_DSD	Age/Sex: 25-49 Female	1,618
GEND_GBV_DSD	Age/Sex: 50+ Female	193
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	9,324
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	12,232
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	6,118
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	768
GEND_GBV_DSD	Age/Sex: 15-19 Female	1,688
GEND_GBV_DSD	Age/Sex: 15-19 male	1,643
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	178,411
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	5,260
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	55,310
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	5,977
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	111,864
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	2,799
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,799
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,460
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	295
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	44
PMTCT_EID_DSD	By infants who received a virologic test within 2 months	10,035

	of birth	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3,463
PMTCT_EID_DSD	Sum of Infant Age disaggregates	13,498
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	293
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	109
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	187,774
TX_CURR_DSD	Age/Sex: 15-19 Male	942
TX_CURR_DSD	Age/Sex: 15-19 Female	1,805
TX_CURR_DSD	Sum of age/sex disaggregates	2,747
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	4,391
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	47,943
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,957
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	89,500
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	9,348
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	137,443
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	146,791
TX_CURR_DSD	Age/Sex: <1	70
TX_CURR_DSD	Age/Sex: <1-9	1,483
TX_CURR_DSD	Age/Sex: 10-14 Male	429
TX_CURR_DSD	Age/Sex: 10-14 Female	418
TX_CURR_DSD	Age/Sex: 20-24 Male	491
TX_CURR_DSD	Age/Sex: 25-49 Male	8,647
TX_CURR_DSD	Age/Sex: 50+ Male	2,027
TX_CURR_DSD	Age/Sex: 20-24 Female	3,288
TX_CURR_DSD	Age/Sex: 25-49 Female	19,168
TX_CURR_DSD	Age/Sex: 50+ Female	2,215
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	54,107



TX_NEW_DSD	By Age/Sex: <1	70
TX_NEW_DSD	By Age/Sex: 1-9	394
TX_NEW_DSD	By Age/Sex: 10-14 Male	116
TX_NEW_DSD	By Age/Sex: 15-19 Male	290
TX_NEW_DSD	By Age/Sex: 20-24 Male	162
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,641
TX_NEW_DSD	By Age/Sex: 50+ Male	691
TX_NEW_DSD	By Age/Sex: 10-14 Female	56
TX_NEW_DSD	By Age/Sex: 15-19 Female	746
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,016
TX_NEW_DSD	By Age/Sex: 25-49 Female	5,152
TX_NEW_DSD	By Age/Sex: 50+ Female	732
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,602
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,652
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	13,253
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,976
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	24,160
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	41,041
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	113,518
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	125,930
TX_PVLS_DSD	Numerator: Indication: Routine	48,833
TX_PVLS_DSD	Numerator: Indication: Targeted	64,685
TX_PVLS_DSD	Denominator: Indication: Routine	54,107
TX_PVLS_DSD	Denominator: Indication: Targeted	71,823
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	3,711
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	36,945
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	4,180



TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	68,682
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	4,102
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	40,995
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	4,610
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	76,223
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	21,114
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	28,232
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	104
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	119
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	938
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	189
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13



	months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	262
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	331
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,522
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	211
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	141
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	40
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	162
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	56



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,249
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	253
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	346
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	439
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,026
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	285



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	861
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,746
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	918
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,807
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,170
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,681
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,245
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,085
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories	142



	that perform this testing	
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	339
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	268
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	68
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	39
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	24
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	2
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	2
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	70
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	21
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	11
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	11



LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	6
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	4
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	2
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	12
LAB_PT_TA	CD4: Number of laboratories that perform this testing	13
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	251
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	195
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	409
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	9
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	38
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	1

Implementing Mechanism Details



Mechanism ID: 16784	Mechanism Name: Sauti za Watanzania
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 11,756,220	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 11,756,220	
Funding Source	Funding Amount
GHP-State	11,756,220

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	3,000,000
Focus Area:	Training of health workers and community outreach workers
Key Populations: FSW	3,000,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	500,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	300,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Condom programming	200,000
Economic Strengthening	500,000
Education	100,000
Food and Nutrition: Commodities	150,000



Food and Nutrition: Policy, Tools, and Service Delivery	150,000
---	---------

Budget Code Information

Mechanism ID:	16784		
Mechanism Name:	Sauti za Watanzania		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	5,484,116	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	4,972,104	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	72,119
PP_PREV_DSD	Total number of people in the target population	120,245
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	72,119
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	42,157
KP_PREV_DSD	Total estimated number of key population in the	59,394



	catchment area	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,652
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	40,107
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	10,156
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	54,388
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	541,682
HTC_TST_DSD	Age/sex: 10-14 Male	10,327
HTC_TST_DSD	Age/sex: 15-19 Male	2,332
HTC_TST_DSD	Age/sex: 20-24 Male	7,759
HTC_TST_DSD	Age/sex: 25-49 Male	29,213
HTC_TST_DSD	Age/sex: 10-14 Female	11,184
HTC_TST_DSD	Age/sex: 15-19 Female	13,382
HTC_TST_DSD	Age/sex: 20-24 Female	12,499
HTC_TST_DSD	Age/sex: 25-49 Female	29,198
HTC_TST_DSD	Sum of Age/Sex disaggregates	115,894
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	387
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	154
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,034
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,425



HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	449
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	499
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,006
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	4,457
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	60,302
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	151,380
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	67,265
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	139,708
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	127,567
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	291,088
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	418,655
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,243
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	8,233
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,471
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	16,809
HTC_TST_DSD	Test Result by Age: Positive: 1-9	274
HTC_TST_DSD	Age/sex: 1-9	7,133
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	145,280
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	396,402

Implementing Mechanism Details

Mechanism ID: 16787	Mechanism Name: Strengthening High Impact Interventions for an AIDS-Free Generation (AIDSFree) Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 8,860,864	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 8,860,864	
Funding Source	Funding Amount
GHP-State	8,860,864

Cross-Cutting Budget Attribution(s)

Condom programming	100,000
Gender: GBV	610,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms

Budget Code Information

Mechanism ID:	16787		
Mechanism Name:	Strengthening High Impact Interventions for an AIDS-Free Generation		
Prime Partner Name:	(AIDSFree) Project John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	40,452	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	25,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	7,214,559	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	326,479	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	254,602	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	928,912	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	70,160	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,709
PMTCT_ART_DSD	New on ART	539
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	278
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,709
PMTCT_STAT_DSD	Number of new ANC and L&D clients	13,375
PMTCT_STAT_DSD	By: Known positives at entry	293
PMTCT_STAT_DSD	By: Number of new positives identified	572



PMTCT_STAT_DSD	Sum of Positives Status disaggregates	865
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	6
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	14
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	27
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	2
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	5
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	10
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	103
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	224
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	493
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	877
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	8
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	20
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	45
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	172,267
VMMC_CIRC_DSD	By Age: 10-14	86,134
VMMC_CIRC_DSD	By Age: 15-19	36,570
VMMC_CIRC_DSD	By Age: 20-24	13,118
VMMC_CIRC_DSD	By Age: 25-29	36,445



VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	135,822
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	172,267
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	172,267
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	347,622
HTC_TST_DSD	Age/sex: 10-14 Male	340
HTC_TST_DSD	Age/sex: 15-19 Male	488
HTC_TST_DSD	Age/sex: 20-24 Male	350
HTC_TST_DSD	Age/sex: 25-49 Male	3,383
HTC_TST_DSD	Age/sex: 50+ Male	721
HTC_TST_DSD	Age/sex: 10-14 Female	406
HTC_TST_DSD	Age/sex: 15-19 Female	800
HTC_TST_DSD	Age/sex: 20-24 Female	1,305
HTC_TST_DSD	Age/sex: 25-49 Female	5,985
HTC_TST_DSD	Age/sex: 50+ Female	670
HTC_TST_DSD	Sum of Age/Sex disaggregates	14,448
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	32
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	27
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	239
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	50
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	23
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	54
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	91
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	415
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	47
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	102,647
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	78,218
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	36,669



	ONLY: <15 Female	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	114,193
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	139,316
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	192,411
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	331,727
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	852
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,721
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	686
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	6,425
HTC_TST_DSD	Test Result by Age: Positive: <1	18
HTC_TST_DSD	Test Result by Age: Positive: 1-9	47
HTC_TST_DSD	Age/sex: <1	350
HTC_TST_DSD	Age/sex: 1-9	1,097
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	8,193
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	25,885
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	6,756
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	71,437
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	43,972
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	6,088
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	172,267
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	13,232
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	10,419
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	326
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,662
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	364

TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	7,067
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	169
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	169
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	154
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	14
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	1
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	646
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	176
PMTCT_EID_DSD	Sum of Infant Age disaggregates	822
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	18
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	6
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	10,974
TX_CURR_DSD	Age/Sex: 15-19 Male	104
TX_CURR_DSD	Age/Sex: 15-19 Female	222
TX_CURR_DSD	Sum of age/sex disaggregates	326
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	209
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,617
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	208
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,880
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	417
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,497
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,914
TX_CURR_DSD	Age/Sex: <1	2
TX_CURR_DSD	Age/Sex: <1-9	152



TX_CURR_DSD	Age/Sex: 10-14 Male	38
TX_CURR_DSD	Age/Sex: 10-14 Female	35
TX_CURR_DSD	Age/Sex: 20-24 Male	18
TX_CURR_DSD	Age/Sex: 25-49 Male	473
TX_CURR_DSD	Age/Sex: 50+ Male	142
TX_CURR_DSD	Age/Sex: 20-24 Female	476
TX_CURR_DSD	Age/Sex: 25-49 Female	2,204
TX_CURR_DSD	Age/Sex: 50+ Female	194
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,854
TX_NEW_DSD	By Age/Sex: <1	2
TX_NEW_DSD	By Age/Sex: 1-9	82
TX_NEW_DSD	By Age/Sex: 10-14 Male	17
TX_NEW_DSD	By Age/Sex: 15-19 Male	88
TX_NEW_DSD	By Age/Sex: 20-24 Male	13
TX_NEW_DSD	By Age/Sex: 25-49 Male	378
TX_NEW_DSD	By Age/Sex: 50+ Male	101
TX_NEW_DSD	By Age/Sex: 10-14 Female	29
TX_NEW_DSD	By Age/Sex: 15-19 Female	189
TX_NEW_DSD	By Age/Sex: 20-24 Female	295
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,260
TX_NEW_DSD	By Age/Sex: 50+ Female	128
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,498
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	77
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	729
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	130
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,336
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,272
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	12,707



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	14,105
TX_PVLS_DSD	Numerator: Indication: Routine	5,282
TX_PVLS_DSD	Numerator: Indication: Targeted	7,425
TX_PVLS_DSD	Denominator: Indication: Routine	5,854
TX_PVLS_DSD	Denominator: Indication: Targeted	8,251
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	344
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	2,988
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	409
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	8,966
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	379
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	3,321
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	454
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	9,951
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,962
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,615
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults	116



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	54
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	74
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	316
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5



TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	37
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	153
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	40
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	71
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	99
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of	421



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	48
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	36
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	318
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	59
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	859
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	52
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	425
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	82



	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,143

Implementing Mechanism Details

Mechanism ID: 16792	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 16820	Mechanism Name: RESPOND TANZANIA PROJECT
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Engender Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 16820			
Mechanism Name: RESPOND TANZANIA PROJECT			
Prime Partner Name: Engender Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16874	Mechanism Name: Local FOA Follow-on - (GH001068)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tanzania Health Promotion Support (THPS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 7,218,304	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,218,304	
Funding Source	Funding Amount
GHP-State	7,218,304

Cross-Cutting Budget Attribution(s)

Human Resources for Health	700,000
Key Populations: MSM and TG	100,000
Focus Area:	Training of health workers and community outreach workers



Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	170,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	250,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	16874
Mechanism Name:	Local FOA Follow-on - (GH001068)



Prime Partner Name: Tanzania Health Promotion Support (THPS)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	200,765	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	80,527	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	13,568	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	173,076	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	742,841	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	967,940	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,129,575	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	410,012	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status	112,027

	(includes women who were tested for HIV and received their results)	
PMTCT_ART_DSD	New on ART	1,474
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	758
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	112,027
PMTCT_STAT_DSD	Number of new ANC and L&D clients	117,930
PMTCT_STAT_DSD	By: Known positives at entry	796
PMTCT_STAT_DSD	By: Number of new positives identified	1,544
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,340
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	1,326
KP_MAT_DSD	Sex: Male	888
KP_MAT_DSD	Sex: Female	438
KP_MAT_DSD	Sum of Sex disaggregates	1,326
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,974
KP_PREV_DSD	Total estimated number of key population in the catchment area	4,912
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	648
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,001
KP_PREV_DSD	By key population type: Males who inject drugs (Male	888



	PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	437
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	998
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,354
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	1,045
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	515
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	453,175
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	56,177
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	93,294
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	55,240
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	248,464
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	111,417
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	341,758



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	453,175
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	610
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,153
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	601
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	7,438
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	564
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	844
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	18,552
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	194,549
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	108,608
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	16,599
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	113,459
GEND_GBV_DSD	Number of people receiving post-GBV care	5,084
GEND_GBV_DSD	Age/Sex: <10 Male	515
GEND_GBV_DSD	Age/Sex: 10-14 Male	637
GEND_GBV_DSD	Age/Sex: 20-24 Male	294
GEND_GBV_DSD	Age/Sex: 25-49 Male	376
GEND_GBV_DSD	Age/Sex: 50+ Male	43
GEND_GBV_DSD	Age/Sex: <10 Female	566
GEND_GBV_DSD	Age/Sex: 10-14 Female	870
GEND_GBV_DSD	Age/Sex: 20-24 Female	357
GEND_GBV_DSD	Age/Sex: 25-49 Female	454
GEND_GBV_DSD	Age/Sex: 50+ Female	52
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	2,588
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,390
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,694
GEND_GBV_DSD	By PEP service provision (related to sexual violence	212



	services provided)	
GEND_GBV_DSD	Age/Sex: 15-19 Female	464
GEND_GBV_DSD	Age/Sex: 15-19 male	456
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	49,368
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,725
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	12,718
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,872
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	33,053
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	785
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	785
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	693
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	81
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	11
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,863
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	361
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,224
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	52
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	9
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	51,965
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,991
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	15,102
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,754



TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	33,118
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,745
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	48,220
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	51,965
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	18,885
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	635
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	5,654
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	693
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	11,903
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	18,885
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	32,103
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	35,627
TX_PVLS_DSD	Numerator: Indication: Routine	17,028
TX_PVLS_DSD	Numerator: Indication: Targeted	15,075
TX_PVLS_DSD	Denominator: Indication: Routine	18,885
TX_PVLS_DSD	Denominator: Indication: Targeted	16,742
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,164
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	9,473
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,142
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	20,324
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,281
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	10,518
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,264
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	22,564
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,821
TX_RET_DSD	Total number of adults and children who initiated ART	6,403



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	222
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,376
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	241
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,982
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	289
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,829
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	325
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,960



LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	59
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	59
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	59
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	52
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	52
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	52
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	50
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	50
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	50
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	2
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	2
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2

Implementing Mechanism Details

Mechanism ID: 16876	Mechanism Name: T-MARC FMP Scale-up
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: T-MARC Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16876			
Mechanism Name: T-MARC FMP Scale-up			
Prime Partner Name: T-MARC Tanzania			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16877	Mechanism Name: DEBI-FBO - (GH000699)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Council of Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,929,142	
---	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,929,142	
Funding Source	Funding Amount
GHP-State	1,929,142

Cross-Cutting Budget Attribution(s)

Gender: GBV	175,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	40,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 16877			
Mechanism Name: DEBI-FBO - (GH000699)			
Prime Partner Name: Christian Council of Tanzania			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,124,485	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	524,657	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	280,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,142
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	3,645
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	4,497

Implementing Mechanism Details

Mechanism ID: 16878	Mechanism Name: DEBI
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation, Tanzania	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16878			
Mechanism Name: DEBI			
Prime Partner Name: African Medical and Research Foundation, Tanzania			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16884	Mechanism Name: DCC Follow-on
----------------------------	--------------------------------------

Approved



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Drug Control Commission	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16884			
Mechanism Name: DCC Follow-on			
Prime Partner Name: Drug Control Commission			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16885	Mechanism Name: MUHAS-TAPP - (GH000837)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Muhimbili University College of Health Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 1,196,465	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,196,465	
Funding Source	Funding Amount
GHP-State	1,196,465

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16885		
Mechanism Name:	MUHAS-TAPP - (GH000837)		
Prime Partner Name:	Muhimbili University College of Health Sciences		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	726,655	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	469,810	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_MAT_DSD	Number of people who inject drugs (PWID) on	999



	medication assisted therapy (MAT) for at least 6 months	
KP_MAT_DSD	Sex: Male	190
KP_MAT_DSD	Sex: Female	809
KP_MAT_DSD	Sum of Sex disaggregates	999
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	44,213
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	600
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,617
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,486
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	16,510
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,086
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	40,127
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	44,213
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	22
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	103
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,786
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,490
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	16,100
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	28,310

Implementing Mechanism Details

Mechanism ID: 16886	Mechanism Name: WHO Follow-on - (GH001180)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 170,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 170,000	
Funding Source	Funding Amount
GHP-State	170,000

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	10,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	10,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Gender: Gender Equality	10,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support



Budget Code Information

Mechanism ID: 16886			
Mechanism Name: WHO Follow-on - (GH001180)			
Prime Partner Name: World Health Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	170,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16887	Mechanism Name: MOHSW - Follow On - (GH001062)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Welfare, Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 390,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 390,000	
Funding Source	Funding Amount
GHP-State	390,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 16887			
Mechanism Name: MOHSW - Follow On - (GH001062)			
Prime Partner Name: Ministry of Health and Social Welfare, Tanzania			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16891	Mechanism Name: CLSI Lab - (GH001114)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 250,000	
Funding Source	Funding Amount
GHP-State	250,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16891			
Mechanism Name: CLSI Lab - (GH001114)			
Prime Partner Name: Clinical and Laboratory Standards Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16892	Mechanism Name: ASCP Lab - (GH001096)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 225,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 225,000	
Funding Source	Funding Amount
GHP-State	225,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16892			
Mechanism Name: ASCP Lab - (GH001096)			
Prime Partner Name: American Society of Clinical Pathology			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16899	Mechanism Name: HIS - UCC follow on - (GH001361)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Management development for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 871,300	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 871,300	
Funding Source	Funding Amount
GHP-State	871,300

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16899		
Mechanism Name:	HIS - UCC follow on - (GH001361)		
Prime Partner Name:	Management development for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	349,300	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	322,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17082	Mechanism Name: ASSIST
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,950,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,950,000	
Funding Source	Funding Amount
GHP-State	3,950,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	800,000
Gender: Gender Equality	100,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Water	100,000

Budget Code Information

Mechanism ID:	17082		
Mechanism Name:	ASSIST		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	CIRC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	850,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	800,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17102	Mechanism Name: MUHAS SPH Follow On - (GH001075)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Muhimbili University College of Health Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 300,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount
GHP-State	300,000



Cross-Cutting Budget Attribution(s)

Human Resources for Health	290,000
Gender: Gender Equality	10,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support

Budget Code Information

Mechanism ID: 17102			
Mechanism Name: MUHAS SPH Follow On - (GH001075)			
Prime Partner Name: Muhimbili University College of Health Sciences			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	86
HRH_PRE	By Graduates: Other	86
HRH_PRE	Sum of Graduates disaggreagtes	86

Implementing Mechanism Details

Mechanism ID: 17103	Mechanism Name: BIPAI-PPP (linked to
----------------------------	---



	BIPAI-PPP 10070)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine International Pediatric AIDS Initiative/Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,945,521	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,945,521	
Funding Source	Funding Amount
GHP-State	1,945,521

Cross-Cutting Budget Attribution(s)

Human Resources for Health	250,000
Food and Nutrition: Policy, Tools, and Service Delivery	148,578
Food and Nutrition: Commodities	29,837
Economic Strengthening	29,494
Education	99,676
Gender: GBV	12,267
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information

Budget Code Information

Mechanism ID:	17103
Mechanism Name:	BIPAI-PPP (linked to BIPAI-PPP 10070)
Prime Partner Name:	Baylor College of Medicine International Pediatric AIDS



Initiative/Tanzania			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	21,450	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	383,432	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,540,639	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	668
HTC_TST_DSD	Age/sex: 10-14 Male	115
HTC_TST_DSD	Age/sex: 15-19 Male	12
HTC_TST_DSD	Age/sex: 20-24 Male	3
HTC_TST_DSD	Age/sex: 25-49 Male	48
HTC_TST_DSD	Age/sex: 50+ Male	12
HTC_TST_DSD	Age/sex: 10-14 Female	5
HTC_TST_DSD	Age/sex: 15-19 Female	16
HTC_TST_DSD	Age/sex: 20-24 Female	18
HTC_TST_DSD	Age/sex: 25-49 Female	73
HTC_TST_DSD	Age/sex: 50+ Female	9
HTC_TST_DSD	Sum of Age/Sex disaggregates	311
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	2



HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	5
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	126
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	53
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	179
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	179
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	2
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	2
HTC_TST_DSD	Test Result by Age: Positive: 1-9	4
HTC_TST_DSD	Age/sex: <1	21
HTC_TST_DSD	Age/sex: 1-9	157
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	57
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	477
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	134
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	5,424
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	222
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	1,457
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	287
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	3,458
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	83
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	83
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	71
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	10
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	2



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,711
TX_CURR_DSD	Age/Sex: 15-19 Male	142
TX_CURR_DSD	Age/Sex: 15-19 Female	254
TX_CURR_DSD	Sum of age/sex disaggregates	396
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	82
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	584
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	72
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,281
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	154
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,865
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,019
TX_CURR_DSD	Age/Sex: <1	8
TX_CURR_DSD	Age/Sex: <1-9	148
TX_CURR_DSD	Age/Sex: 10-14 Male	47
TX_CURR_DSD	Age/Sex: 10-14 Female	39
TX_CURR_DSD	Age/Sex: 20-24 Male	42
TX_CURR_DSD	Age/Sex: 25-49 Male	640
TX_CURR_DSD	Age/Sex: 50+ Male	168
TX_CURR_DSD	Age/Sex: 20-24 Female	367
TX_CURR_DSD	Age/Sex: 25-49 Female	1,636
TX_CURR_DSD	Age/Sex: 50+ Female	201
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	754
TX_NEW_DSD	By Age/Sex: <1	8
TX_NEW_DSD	By Age/Sex: 1-9	18
TX_NEW_DSD	By Age/Sex: 10-14 Male	5
TX_NEW_DSD	By Age/Sex: 15-19 Male	30
TX_NEW_DSD	By Age/Sex: 20-24 Male	7
TX_NEW_DSD	By Age/Sex: 25-49 Male	118
TX_NEW_DSD	By Age/Sex: 50+ Male	30
TX_NEW_DSD	By Age/Sex: 10-14 Female	3



TX_NEW_DSD	By Age/Sex: 15-19 Female	56
TX_NEW_DSD	By Age/Sex: 20-24 Female	63
TX_NEW_DSD	By Age/Sex: 25-49 Female	253
TX_NEW_DSD	By Age/Sex: 50+ Female	35
TX_NEW_DSD	Sum of Age/Sex disaggregates	600
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	8
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	36
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	8
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	76
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	128
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,182
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,421
TX_PVLS_DSD	Numerator: Indication: Routine	680
TX_PVLS_DSD	Numerator: Indication: Targeted	1,502
TX_PVLS_DSD	Denominator: Indication: Routine	754
TX_PVLS_DSD	Denominator: Indication: Targeted	1,667
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	75
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	614
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	77
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	1,416
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	82
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	683
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	85
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,571
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	412
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	551



	period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	114



TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	71
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	18



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	33
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	38
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	153
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on	8



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	78
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	49
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	104

Implementing Mechanism Details

Mechanism ID: 17151	Mechanism Name: SPIRES
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17151			
Mechanism Name: ASPIRES			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17292	Mechanism Name: APHL Lab Follow on - (GH001097)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 450,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 450,000	
Funding Source	Funding Amount
GHP-State	450,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17292			
Mechanism Name: APHL Lab Follow on - (GH001097)			
Prime Partner Name: Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17293	Mechanism Name: MDH Kagera - (GH001179)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Management development for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 18,958,980	
Applied Pipeline Amount: 13,033,510	
Total All Funding Sources and Applied Pipeline Amount: 31,992,490	
Funding Source	Funding Amount
GHP-State	18,958,980

Cross-Cutting Budget Attribution(s)

Human Resources for Health	800,000
Food and Nutrition: Policy, Tools, and Service Delivery	200,000
Key Populations: MSM and TG	70,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	70,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	1,000,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	500,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	17293
----------------------	--------------



Mechanism Name: MDH Kagera - (GH001179)			
Prime Partner Name: Management development for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	3,115,969	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	642,812	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	213,653	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	645,132	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	3,115,894	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	10,280,789	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	944,731	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	198,328
PMTCT_ART_DSD	New on ART	8,389
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,783
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	198,328
PMTCT_STAT_DSD	Number of new ANC and L&D clients	208,779
PMTCT_STAT_DSD	By: Known positives at entry	3,973
PMTCT_STAT_DSD	By: Number of new positives identified	8,830
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	12,803
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	8
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	139
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	398
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	62
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	207
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	287
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	2,448
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	7,421
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	32,817



PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	552
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	848
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	9
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	1,591
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	22
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	2,606
KP_MAT_DSD	Sex: Male	1,304
KP_MAT_DSD	Sex: Female	1,302
KP_MAT_DSD	Sum of Sex disaggregates	2,606
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	57,445
VMMC_CIRC_DSD	By Age: 10-14	28,723
VMMC_CIRC_DSD	By Age: 15-19	15,109
VMMC_CIRC_DSD	By Age: 20-24	6,538
VMMC_CIRC_DSD	By Age: 25-29	7,075
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	50,370
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	57,445
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	57,445
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,224,706
HTC_TST_DSD	Age/sex: 10-14 Male	3,741
HTC_TST_DSD	Age/sex: 15-19 Male	6,837
HTC_TST_DSD	Age/sex: 20-24 Male	689
HTC_TST_DSD	Age/sex: 25-49 Male	32,152



HTC_TST_DSD	Age/sex: 50+ Male	8,289
HTC_TST_DSD	Age/sex: 10-14 Female	5,905
HTC_TST_DSD	Age/sex: 15-19 Female	8,960
HTC_TST_DSD	Age/sex: 20-24 Female	17,957
HTC_TST_DSD	Age/sex: 25-49 Female	75,999
HTC_TST_DSD	Age/sex: 50+ Female	6,235
HTC_TST_DSD	Sum of Age/Sex disaggregates	166,764
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	177
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	478
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	44
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	2,241
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	581
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	279
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	536
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,088
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	4,587
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	376
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	156,460
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	259,439
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	125,247
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	496,462
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	281,707
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	755,901
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,037,608
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	2,186
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	14,728
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	2,147



	Female	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	27,653
HTC_TST_DSD	Test Result by Age: Positive: <1	285
HTC_TST_DSD	Test Result by Age: Positive: 1-9	677
HTC_TST_DSD	Age/sex: <1	5,979
HTC_TST_DSD	Age/sex: 1-9	14,355
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	55,219
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	584,723
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	270,805
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	50,006
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	57,445
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	206,508
GEND_GBV_DSD	Number of people receiving post-GBV care	24,014
GEND_GBV_DSD	Age/Sex: <10 Male	2,432
GEND_GBV_DSD	Age/Sex: 10-14 Male	2,980
GEND_GBV_DSD	Age/Sex: 20-24 Male	1,407
GEND_GBV_DSD	Age/Sex: 25-49 Male	1,807
GEND_GBV_DSD	Age/Sex: 50+ Male	217
GEND_GBV_DSD	Age/Sex: <10 Female	2,671
GEND_GBV_DSD	Age/Sex: 10-14 Female	3,989
GEND_GBV_DSD	Age/Sex: 20-24 Female	1,701
GEND_GBV_DSD	Age/Sex: 25-49 Female	2,142
GEND_GBV_DSD	Age/Sex: 50+ Female	266
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	12,072
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	16,005
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	8,009
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,021
GEND_GBV_DSD	Age/Sex: 15-19 Female	2,236
GEND_GBV_DSD	Age/Sex: 15-19 male	2,166



TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	233,075
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	6,221
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	60,146
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	6,585
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	160,123
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3,790
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,790
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	3,305
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	413
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	72
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	10,356
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,810
PMTCT_EID_DSD	Sum of Infant Age disaggregates	12,166
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	136
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	57
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	245,337
TX_CURR_DSD	Age/Sex: 15-19 Male	1,003
TX_CURR_DSD	Age/Sex: 15-19 Female	2,669
TX_CURR_DSD	Sum of age/sex disaggregates	3,672
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,409
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	34,537
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5,054



TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	144,598
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	10,463
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	179,135
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	189,598
TX_CURR_DSD	Age/Sex: <1	40
TX_CURR_DSD	Age/Sex: <1-9	2,343
TX_CURR_DSD	Age/Sex: 10-14 Male	495
TX_CURR_DSD	Age/Sex: 10-14 Female	509
TX_CURR_DSD	Age/Sex: 20-24 Male	120
TX_CURR_DSD	Age/Sex: 25-49 Male	5,054
TX_CURR_DSD	Age/Sex: 50+ Male	1,479
TX_CURR_DSD	Age/Sex: 20-24 Female	7,121
TX_CURR_DSD	Age/Sex: 25-49 Female	32,432
TX_CURR_DSD	Age/Sex: 50+ Female	2,474
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	108,859
TX_NEW_DSD	By Age/Sex: <1	40
TX_NEW_DSD	By Age/Sex: 1-9	794
TX_NEW_DSD	By Age/Sex: 10-14 Male	177
TX_NEW_DSD	By Age/Sex: 15-19 Male	515
TX_NEW_DSD	By Age/Sex: 20-24 Male	49
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,419
TX_NEW_DSD	By Age/Sex: 50+ Male	625
TX_NEW_DSD	By Age/Sex: 10-14 Female	385
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,500
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,010
TX_NEW_DSD	By Age/Sex: 25-49 Female	12,743
TX_NEW_DSD	By Age/Sex: 50+ Female	1,042
TX_NEW_DSD	Sum of Age/Sex disaggregates	22,465
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2,693
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	16,467
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,608



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	63,792
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	85,560
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	166,799
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	184,915
TX_PVLS_DSD	Numerator: Indication: Routine	98,212
TX_PVLS_DSD	Numerator: Indication: Targeted	68,587
TX_PVLS_DSD	Denominator: Indication: Routine	108,860
TX_PVLS_DSD	Denominator: Indication: Targeted	76,055
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	4,969
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	30,258
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	4,941
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	126,631
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	5,479
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	33,569
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	5,458
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	140,409
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	20,738
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	27,647
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	138
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults	26



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	88
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	416
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	105
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	67
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	256
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	524
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,199
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	179
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and	177



	children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	33
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	111
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	557
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	140
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	341



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	691
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,925
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	235
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	510
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,726
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	551
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,942
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	682



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,971
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	739
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,947
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	153
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	153
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	153
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	44
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	44
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	44
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	2
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	2
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this	2



	testing	
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	2
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	58
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	58
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	58
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	8
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	8
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	8
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	162
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	162
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	161



LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	26
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	26
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	27

Implementing Mechanism Details

Mechanism ID: 17294	Mechanism Name: MOHSW Lab Follow on - (GH001603)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Welfare, Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 190,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 190,000	
Funding Source	Funding Amount
GHP-State	190,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17294
Mechanism Name:	MOHSW Lab Follow on - (GH001603)
Prime Partner Name:	Ministry of Health and Social Welfare, Tanzania



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	140,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	50,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17295	Mechanism Name: ASM Lab Follow on
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 17295			
Mechanism Name: ASM Lab Follow on			
Prime Partner Name: American Society for Microbiology			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17296	Mechanism Name: CDC PPP Management - (GH001531)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Cardno Emerging Markets	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,325,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,325,000	
Funding Source	Funding Amount
GHP-State	1,325,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	200,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care



Budget Code Information

Mechanism ID: 17296			
Mechanism Name: CDC PPP Management - (GH001531)			
Prime Partner Name: Cardno Emerging Markets			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	325,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	750,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17300	Mechanism Name: NIMR Follow On - (GH001633)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Institute for Medical Research	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 300,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount



GHP-State	300,000
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17300			
Mechanism Name: NIMR Follow On - (GH001633)			
Prime Partner Name: National Institute for Medical Research			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	225,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	37
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	33
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	12
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	24



LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	9
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	18
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	5
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1

Implementing Mechanism Details

Mechanism ID: 17304	Mechanism Name: University Partnership Field Epidemiology Expansion - (GH001304)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	Funding Amount
GHP-State	300,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
----------------------------	---------



Budget Code Information

Mechanism ID:	17304		
Mechanism Name:	University Partnership Field Epidemiology Expansion - (GH001304)		
Prime Partner Name:	University of Washington		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17305	Mechanism Name: Twinning follow On (U7HA04128)
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,900,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,900,000	
Funding Source	Funding Amount
GHP-State	1,900,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	800,000
----------------------------	---------



Food and Nutrition: Policy, Tools, and Service Delivery	500,000
Key Populations: MSM and TG	40,000
Focus Area:	Training of health workers and community outreach workers
Key Populations: FSW	40,000
Gender: GBV	50,000
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Gender: Gender Equality	50,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building

Budget Code Information

Mechanism ID: 17305			
Mechanism Name: Twinning follow On (U7HA04128)			
Prime Partner Name: American International Health Alliance			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	900,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	3,475
HRH_PRE	By Graduates: Nurses	3,475
HRH_PRE	By Graduates: Social service workers	0
HRH_PRE	Sum of Graduates disaggreagtes	3,475

Implementing Mechanism Details

Mechanism ID: 17316	Mechanism Name: UNICEF Follow on - (GH001619)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,050,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,050,000	
Funding Source	Funding Amount
GHP-State	1,050,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	200,000
-------------	---------



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	200,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and



	support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Budget Code Information

Mechanism ID: 17316			
Mechanism Name: UNICEF Follow on - (GH001619)			
Prime Partner Name: United Nations Children's Fund			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17343	Mechanism Name: MOHSW Blood Follow on - (GH001613)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: Ministry of Health and Social Welfare, Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 120,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 120,000	
Funding Source	Funding Amount
GHP-State	120,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17343		
Mechanism Name:	MOHSW Blood Follow on - (GH001613)		
Prime Partner Name:	Ministry of Health and Social Welfare, Tanzania		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	120,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17357	Mechanism Name: Supporting Operational AIDS Research Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,242,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,242,000	
Funding Source	Funding Amount
GHP-State	1,242,000

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information

Budget Code Information

Mechanism ID: 17357			
Mechanism Name: Supporting Operational AIDS Research Project			
Prime Partner Name: Population Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	592,000	0
-----------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17358	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17409	Mechanism Name: Maternal and Child Survival Program (MCSP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,780,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,780,000	
Funding Source	Funding Amount
GHP-State	1,780,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	735,251
----------------------------	---------



Budget Code Information

Mechanism ID: 17409			
Mechanism Name: Maternal and Child Survival Program (MCSP)			
Prime Partner Name: JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	980,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	800,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	1,257
HRH_PRE	By Graduates: Nurses	564
HRH_PRE	By Graduates: Midwives	564
HRH_PRE	By Graduates: Other	129
HRH_PRE	Sum of Graduates disaggreagtes	1,257

Implementing Mechanism Details

Mechanism ID: 17416	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17420	Mechanism Name: Challenge TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,348,105	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,348,105	
Funding Source	Funding Amount
GHP-State	1,348,105

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17420		
Mechanism Name:	Challenge TB		
Prime Partner Name:	KNCV Tuberculosis Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,319,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	29,105	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for	17,395

	HIV and received their test results during the past 12 months	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,225
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	13,170
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	17,395
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	17,395
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,448
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,546
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	17,395
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	17,913
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	17,913
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11,079
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,834
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5,508
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	5,855
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,818
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The	2,690



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
--	---	--

Implementing Mechanism Details

Mechanism ID: 17970	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17975	Mechanism Name: ICAP Combination Prevention and Technical Assistance. - (GH000994)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,079,144	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,079,144	
Funding Source	Funding Amount
GHP-State	2,079,144

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17975
----------------------	--------------



Mechanism Name:	ICAP Combination Prevention and Technical Assistance. - (GH000994)		
Prime Partner Name:	Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	187,326	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,891,818	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	31,160
PP_PREV_DSD	Total number of people in the target population	45,360
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	31,160
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	12,545
KP_PREV_DSD	Total estimated number of key population in the catchment area	19,492
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	789
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,756



KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,162
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	18,330
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	19,412
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,784
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,976
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,724
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,928
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,508
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	9,904
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	19,412
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	96
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	288
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	192
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	392
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	7,764
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	11,648

Implementing Mechanism Details

Approved



Mechanism ID: 17982	Mechanism Name: HIV Community Care and Support Study
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: ICF Macro	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 350,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 350,000	
Funding Source	Funding Amount
GHP-State	350,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17982			
Mechanism Name: HIV Community Care and Support Study			
Prime Partner Name: ICF Macro			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	350,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 17983	Mechanism Name: TBD GoT TB Follow On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: TBD	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 750,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 750,000	
Funding Source	Funding Amount
GHP-State	750,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17983		
Mechanism Name:	TBD GoT TB Follow On		
Prime Partner Name:	TBD		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	750,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	21,026



	months	
HTC_TST_DSD	Age/sex: 10-14 Male	138
HTC_TST_DSD	Age/sex: 15-19 Male	187
HTC_TST_DSD	Age/sex: 20-24 Male	34
HTC_TST_DSD	Age/sex: 25-49 Male	1,203
HTC_TST_DSD	Age/sex: 50+ Male	257
HTC_TST_DSD	Age/sex: 10-14 Female	187
HTC_TST_DSD	Age/sex: 15-19 Female	254
HTC_TST_DSD	Age/sex: 20-24 Female	511
HTC_TST_DSD	Age/sex: 25-49 Female	2,430
HTC_TST_DSD	Age/sex: 50+ Female	185
HTC_TST_DSD	Sum of Age/Sex disaggregates	5,386
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	41
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	317
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	47
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	3
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	50
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	126
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	718
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	32
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,706
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,815
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,729
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	9,645
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,435
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	14,460



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	17,895
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	15
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	789
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	15
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,826
HTC_TST_DSD	Test Result by Age: Positive: <1	2
HTC_TST_DSD	Test Result by Age: Positive: 1-9	13
HTC_TST_DSD	Age/sex: <1	177
HTC_TST_DSD	Age/sex: 1-9	631
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	522
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	6,246
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	2,816
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	419
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	2,800
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	8,304
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	13,210
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	21,632
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	21,632
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13,272
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,360
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	8,043



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	8,558
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,332
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,711

Implementing Mechanism Details

Mechanism ID: 17984	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17985	Mechanism Name: TBD Blood Safety TA - (GH001565)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: TBD	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 420,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 420,000	
Funding Source	Funding Amount
GHP-State	420,000

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 17985			
Mechanism Name: TBD Blood Safety TA - (GH001565)			
Prime Partner Name: TBD			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	420,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17986	Mechanism Name: Local FOA TBD1 - (GH002021)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ariel Glaser Pediatric AIDS Healthcare Initiative	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 25,873,992	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 25,873,992	
Funding Source	Funding Amount
GHP-State	25,873,992

Cross-Cutting Budget Attribution(s)



Key Populations: MSM and TG	300,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	300,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	658,026
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	600,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and



	support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	2,000,000

Budget Code Information

Mechanism ID: 17986			
Mechanism Name: Local FOA TBD1 - (GH002021)			
Prime Partner Name: Ariel Glaser Pediatric AIDS Healthcare Initiative			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	910,675	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	499,649	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	84,595	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	5,803,573	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	16,906,906	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,668,594	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	442,889
PMTCT_ART_DSD	New on ART	12,810
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,821
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	442,889
PMTCT_STAT_DSD	Number of new ANC and L&D clients	466,201
PMTCT_STAT_DSD	By: Known positives at entry	5,066
PMTCT_STAT_DSD	By: Number of new positives identified	13,485
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	18,551
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	108
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	235
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	505
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	35
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	70
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	167
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	3,379
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	7,019
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	14,615



PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	16,264
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	90
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	209
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	1
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	673
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	4
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	2,170
VMMC_CIRC_DSD	By Age: 10-14	1,085
VMMC_CIRC_DSD	By Age: 15-19	1,085
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	2,170
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	2,170
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	2,170
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,018,392
HTC_TST_DSD	Age/sex: 10-14 Male	4,283
HTC_TST_DSD	Age/sex: 15-19 Male	788
HTC_TST_DSD	Age/sex: 20-24 Male	2,738
HTC_TST_DSD	Age/sex: 25-49 Male	28,288
HTC_TST_DSD	Age/sex: 50+ Male	7,987
HTC_TST_DSD	Age/sex: 10-14 Female	1,061
HTC_TST_DSD	Age/sex: 15-19 Female	3,033
HTC_TST_DSD	Age/sex: 20-24 Female	8,772
HTC_TST_DSD	Age/sex: 25-49 Female	36,533
HTC_TST_DSD	Age/sex: 50+ Female	6,539



HTC_TST_DSD	Sum of Age/Sex disaggregates	100,022
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	18
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	37
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	120
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,214
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	340
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	11
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	200
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	589
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,366
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	415
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	103,560
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	199,714
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	64,315
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	533,735
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	167,875
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	733,449
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	901,324
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,404
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	9,314
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,229
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	21,789
HTC_TST_DSD	Test Result by Age: Positive: <1	13
HTC_TST_DSD	Test Result by Age: Positive: 1-9	137
HTC_TST_DSD	Age/sex: <1	2,844



HTC_TST_DSD	Age/sex: 1-9	14,202
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	24,983
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	259,729
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	168,100
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	20,716
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	2,170
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	542,705
GEND_GBV_DSD	Number of people receiving post-GBV care	22,391
GEND_GBV_DSD	Age/Sex: <10 Male	2,244
GEND_GBV_DSD	Age/Sex: 10-14 Male	2,756
GEND_GBV_DSD	Age/Sex: 20-24 Male	1,295
GEND_GBV_DSD	Age/Sex: 25-49 Male	1,659
GEND_GBV_DSD	Age/Sex: 50+ Male	189
GEND_GBV_DSD	Age/Sex: <10 Female	2,459
GEND_GBV_DSD	Age/Sex: 10-14 Female	3,958
GEND_GBV_DSD	Age/Sex: 20-24 Female	1,568
GEND_GBV_DSD	Age/Sex: 25-49 Female	1,987
GEND_GBV_DSD	Age/Sex: 50+ Female	237
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	11,417
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	14,920
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	7,471
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	930
GEND_GBV_DSD	Age/Sex: 15-19 Female	2,047
GEND_GBV_DSD	Age/Sex: 15-19 male	1,992
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	217,756
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	7,277
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	66,020
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	8,780



TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	135,679
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3,355
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,355
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,951
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	355
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	49
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	11,950
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	5,690
PMTCT_EID_DSD	Sum of Infant Age disaggregates	17,640
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	271
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	138
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	229,242
TX_CURR_DSD	Age/Sex: 15-19 Male	539
TX_CURR_DSD	Age/Sex: 15-19 Female	940
TX_CURR_DSD	Sum of age/sex disaggregates	1,479
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	6,590
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	55,077
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	6,267
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	120,988
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	12,857
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	176,065
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	188,922
TX_CURR_DSD	Age/Sex: <1	52
TX_CURR_DSD	Age/Sex: <1-9	1,570



TX_CURR_DSD	Age/Sex: 10-14 Male	457
TX_CURR_DSD	Age/Sex: 10-14 Female	350
TX_CURR_DSD	Age/Sex: 20-24 Male	784
TX_CURR_DSD	Age/Sex: 25-49 Male	9,230
TX_CURR_DSD	Age/Sex: 50+ Male	2,512
TX_CURR_DSD	Age/Sex: 20-24 Female	3,968
TX_CURR_DSD	Age/Sex: 25-49 Female	17,303
TX_CURR_DSD	Age/Sex: 50+ Female	2,615
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	62,291
TX_NEW_DSD	By Age/Sex: <1	52
TX_NEW_DSD	By Age/Sex: 1-9	452
TX_NEW_DSD	By Age/Sex: 10-14 Male	74
TX_NEW_DSD	By Age/Sex: 15-19 Male	175
TX_NEW_DSD	By Age/Sex: 20-24 Male	283
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,491
TX_NEW_DSD	By Age/Sex: 50+ Male	1,034
TX_NEW_DSD	By Age/Sex: 10-14 Female	64
TX_NEW_DSD	By Age/Sex: 15-19 Female	530
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,323
TX_NEW_DSD	By Age/Sex: 25-49 Female	6,057
TX_NEW_DSD	By Age/Sex: 50+ Female	1,104
TX_NEW_DSD	Sum of Age/Sex disaggregates	14,135
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,935
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	14,804
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,043
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	28,870
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	47,652
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	137,068



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	152,041
TX_PVLS_DSD	Numerator: Indication: Routine	56,245
TX_PVLS_DSD	Numerator: Indication: Targeted	80,823
TX_PVLS_DSD	Denominator: Indication: Routine	62,291
TX_PVLS_DSD	Denominator: Indication: Targeted	89,750
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	4,873
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	41,718
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	4,800
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	85,677
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	5,368
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	46,277
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	5,294
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	95,102
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	27,271
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	36,388
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	168
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	28
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	57
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults	107



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,167
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	330
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	175
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	544
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,057
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	356
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	222
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	35



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	73
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	145
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,555
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	441
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	231
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	721



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,745
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	471
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,010
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,858
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,068
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,319
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,348
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,144
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total	1,431



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17,785
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	53
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	35
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	35
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	8
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	2
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	6
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	3
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	3
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	1

Implementing Mechanism Details

Mechanism ID: 17987	Mechanism Name: TBD Institutional Capacity Building TA - (GH001929)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: TBD	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,940,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,940,000	
Funding Source	Funding Amount
GHP-State	1,940,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
----------------------------	---------

Budget Code Information

Mechanism ID: 17987			
Mechanism Name: TBD Institutional Capacity Building TA - (GH001929)			
Prime Partner Name: TBD			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	660,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	950,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	HTXS	280,000	0
-----------	------	---------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17988	Mechanism Name: TBD Surveillance TA - (GH000977)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: TBD	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,600,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,600,000	
Funding Source	Funding Amount
GHP-State	2,600,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17988		
Mechanism Name:	TBD Surveillance TA - (GH000977)		
Prime Partner Name:	TBD		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,850,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	600,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17990	Mechanism Name: TBD Clinical TA (International) - (GH001950)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,200,000	
Funding Source	Funding Amount
GHP-State	3,200,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17990			
Mechanism Name: TBD Clinical TA (International) - (GH001950)			
Prime Partner Name: University of Maryland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17991	Mechanism Name: TBD Comprehensive High Impact HIV Prevention IP (Local) - (GH002018)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,918,868	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,918,868	
Funding Source	Funding Amount
GHP-State	4,918,868

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

Mechanism ID: 17991			
Mechanism Name: TBD Comprehensive High Impact HIV Prevention IP (Local) - (GH002018)			
Prime Partner Name: Columbia University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	3,130,518	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,082,540	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	405,810	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,401
PP_PREV_DSD	Total number of people in the target population	13,714
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	7,401



KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	17,296
KP_PREV_DSD	Total estimated number of key population in the catchment area	35,089
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,222
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,565
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,031
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,478
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	4,245
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	20,334
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key	6,151



	population in the catchment area)	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	4,359
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	324,407
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	28,344
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	53,956
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	84,038
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	158,069
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	112,382
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	212,025
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	324,407
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	415
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,714
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,243
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	11,164
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	92,986
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	231,499

Implementing Mechanism Details

Mechanism ID: 17992	Mechanism Name: TBD Multilateral AIDS Sector Follow On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: TBD	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	200,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17992			
Mechanism Name: TBD Multilateral AIDS Sector Follow On			
Prime Partner Name: TBD			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17993	Mechanism Name: TBD GoT AIDS Sector Follow On - (GH002170)
----------------------------	---



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tanzania Commission for AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 100,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 100,000	
Funding Source	Funding Amount
GHP-State	100,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17993			
Mechanism Name: TBD GoT AIDS Sector Follow On - (GH002170)			
Prime Partner Name: Tanzania Commission for AIDS			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Approved



Mechanism ID: 18056	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18057	Mechanism Name: YouthPower: Implementation- Task Order 1.
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18057		
Mechanism Name:	YouthPower: Implementation- Task Order 1.		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18058	Mechanism Name: Strengthening Health Outcomes through the Private Sector in Tanzania (SHOPS+)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 350,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 350,000	
Funding Source	Funding Amount
GHP-State	350,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18058		
Mechanism Name:	Strengthening Health Outcomes through the Private Sector in Tanzania (SHOPS+)		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	350,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18059	Mechanism Name: Advancing Partners and Communities
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:
Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18059		
Mechanism Name:	Advancing Partners and Communities		
Prime Partner Name:	John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18060	Mechanism Name: Boresha Afya Northern Zone
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 8,907,563	
Applied Pipeline Amount: 7,228,688	
Total All Funding Sources and Applied Pipeline Amount: 16,136,251	
Funding Source	Funding Amount
GHP-State	8,907,563

Cross-Cutting Budget Attribution(s)

Gender: GBV	380,376
Focus Area:	Post GBV Care
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	782,976
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Water	50,000



Budget Code Information

Mechanism ID: 18060			
Mechanism Name: Boresha Afya Northern Zone			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	527,174	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	268,167	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	7,013,672	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,098,550	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	303,181



PMTCT_ART_DSD	New on ART	4,917
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,206
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	303,181
PMTCT_STAT_DSD	Number of new ANC and L&D clients	319,152
PMTCT_STAT_DSD	By: Known positives at entry	2,318
PMTCT_STAT_DSD	By: Number of new positives identified	5,174
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	7,492
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	699,146
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	52,254
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	155,930
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	40,181
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	450,781
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	92,435
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	606,711
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	699,146
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	880
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	6,345
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	833
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	12,665
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	24,656
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	263,683

HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	85,327
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	17,503
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	307,977
GEND_GBV_DSD	Number of people receiving post-GBV care	12,625
GEND_GBV_DSD	Age/Sex: <10 Male	1,267
GEND_GBV_DSD	Age/Sex: 10-14 Male	1,554
GEND_GBV_DSD	Age/Sex: 20-24 Male	740
GEND_GBV_DSD	Age/Sex: 25-49 Male	939
GEND_GBV_DSD	Age/Sex: 50+ Male	92
GEND_GBV_DSD	Age/Sex: <10 Female	1,390
GEND_GBV_DSD	Age/Sex: 10-14 Female	2,214
GEND_GBV_DSD	Age/Sex: 20-24 Female	887
GEND_GBV_DSD	Age/Sex: 25-49 Female	1,114
GEND_GBV_DSD	Age/Sex: 50+ Female	127
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	6,425
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	8,419
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	4,206
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	531
GEND_GBV_DSD	Age/Sex: 15-19 Female	1,163
GEND_GBV_DSD	Age/Sex: 15-19 male	1,138
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	122,724
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	4,712
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	34,510
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	4,905
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	78,597
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,899
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,899

TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,688
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	192
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	19
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	5,407
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,719
PMTCT_EID_DSD	Sum of Infant Age disaggregates	7,126
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	155
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	46
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	129,212
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,008
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	37,541
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,298
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	82,365
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	9,306
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	119,906
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	129,212
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	29,355
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,069
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	8,184
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,128
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	18,974
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	29,355
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml)	72,653



	documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	80,636
TX_PVLS_DSD	Numerator: Indication: Routine	26,511
TX_PVLS_DSD	Numerator: Indication: Targeted	46,142
TX_PVLS_DSD	Denominator: Indication: Routine	29,355
TX_PVLS_DSD	Denominator: Indication: Targeted	51,281
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,754
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	20,946
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,619
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	46,334
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,034
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	23,246
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,883
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	51,473
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15,210
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	20,294
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	696
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,330
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	742
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on	9,442



	treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	925
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,795
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	980
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,594
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	187
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	166
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	130
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	77
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	63
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	30
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1



LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	6
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	120
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	109
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	109
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	7
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	6
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	2
LAB_PT_TA	CD4: Number of laboratories that perform this testing	2
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	165



LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	164
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	165
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	2
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	2

Implementing Mechanism Details

Mechanism ID: 18061	Mechanism Name: Health Policy Plus (HP+)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 650,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 650,000	
Funding Source	Funding Amount
GHP-State	650,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information



Mechanism ID: 18061			
Mechanism Name: Health Policy Plus (HP+)			
Prime Partner Name: Futures Group			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18072	Mechanism Name: Results-based Financing
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 7,000,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,000,000	
Funding Source	Funding Amount
GHP-State	7,000,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	500,000
----------------------------	---------



Budget Code Information

Mechanism ID: 18072			
Mechanism Name: Results-based Financing			
Prime Partner Name: New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,000,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18130	Mechanism Name: TBD
Funding Agency: DOD	Procurement Type: Contract
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 250,000	
Funding Source	Funding Amount
GHP-State	250,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18130			
Mechanism Name: TBD			
Prime Partner Name: Research Triangle International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18131	Mechanism Name: VMMC Follow on - (GH002031)
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 10,240,791	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 10,240,791	
Funding Source	Funding Amount
GHP-State	10,240,791



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18131		
Mechanism Name:	VMMC Follow on - (GH002031)		
Prime Partner Name:	IntraHealth International, Inc		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	9,998,703	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	242,088	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	256,529
VMMC_CIRC_DSD	By Age: 10-14	128,265
VMMC_CIRC_DSD	By Age: 15-19	80,231
VMMC_CIRC_DSD	By Age: 20-24	11,274
VMMC_CIRC_DSD	By Age: 25-29	36,759
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	219,770
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	256,529
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	256,529
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	256,529



	months	
HTC_TST_DSD	Age/sex: 10-14 Male	4,754
HTC_TST_DSD	Age/sex: 15-19 Male	215
HTC_TST_DSD	Age/sex: 20-24 Male	995
HTC_TST_DSD	Age/sex: 25-49 Male	10,133
HTC_TST_DSD	Age/sex: 50+ Male	2,858
HTC_TST_DSD	Age/sex: 10-14 Female	1,098
HTC_TST_DSD	Age/sex: 15-19 Female	899
HTC_TST_DSD	Age/sex: 20-24 Female	2,916
HTC_TST_DSD	Age/sex: 25-49 Female	12,394
HTC_TST_DSD	Age/sex: 50+ Female	2,262
HTC_TST_DSD	Sum of Age/Sex disaggregates	38,524
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	31
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	14
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	45
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	416
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	121
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	27
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	58
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	195
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	791
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	147
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	64,720
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	43,850
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	19,454
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	70,625
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	84,174
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	114,475



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	198,649
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	553
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,536
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	436
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,094
HTC_TST_DSD	Test Result by Age: Positive: <1	38
HTC_TST_DSD	Test Result by Age: Positive: 1-9	170
HTC_TST_DSD	Age/sex: <1	3,299
HTC_TST_DSD	Age/sex: 1-9	16,057
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	255,343

Implementing Mechanism Details

Mechanism ID: 18170	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18171	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18197	Mechanism Name: Health Finance and Governance
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Approved



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18197		
Mechanism Name:	Health Finance and Governance		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18198	Mechanism Name: Global Health Supply Chain-Procurement and Supply Management (GHSC-PSM)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 115,402,195	
Applied Pipeline Amount: 9,468,713	
Total All Funding Sources and Applied Pipeline Amount: 124,870,908	
Funding Source	Funding Amount
GHP-State	115,402,195

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18198		
Mechanism Name:	Global Health Supply Chain- Procurement and Supply Management		
Prime Partner Name:	(GHSC-PSM) Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,035,600	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	3,966,746	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,853,476	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXD	94,222,572	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	14,323,801	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
INVS_COMD	Number of HIV Test Kits purchased	79,203
INVS_COMD	Number of HIV CD4 Reagents purchased	42,838
INVS_COMD	Number of HIV Viral Load Reagents purchased	830,206
INVS_COMD	Number of HIV ARVs purchased	657,294
INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	2,722,348
INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	1,223,025
INVS_COMD	Condoms: Dollars planned (COP)/ spent (Actual)	1,006,557

Implementing Mechanism Details

Mechanism ID: 18199	Mechanism Name: HRH2030
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Chemonics International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	200,000

Cross-Cutting Budget Attribution(s)



Human Resources for Health	200,000
----------------------------	---------

Budget Code Information

Mechanism ID: 18199			
Mechanism Name: HRH2030			
Prime Partner Name: Chemonics International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18200	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18201	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18202	Mechanism Name: Citizens Engaging in Government Oversight (CEGO)- TACOSODE
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18202			
Mechanism Name: Citizens Engaging in Government Oversight (CEGO)- TACOSODE			
Prime Partner Name: New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18237	Mechanism Name: Boresha Afya Southern Zone
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Deloitte Consulting Limited	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 13,697,663	
Applied Pipeline Amount: 4,897,000	
Total All Funding Sources and Applied Pipeline Amount: 18,594,663	
Funding Source	Funding Amount
GHP-State	13,697,663

Cross-Cutting Budget Attribution(s)

Gender: GBV	300,047
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	964,138
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Water	50,000

Budget Code Information

Mechanism ID: 18237



Mechanism Name: Boresha Afya Southern Zone			
Prime Partner Name: Deloitte Consulting Limited			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,458,255	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	659,567	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	311,315	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,731,397	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	7,781,590	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	755,539	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	153,389
PMTCT_ART_DSD	New on ART	5,505
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,024
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	153,389
PMTCT_STAT_DSD	Number of new ANC and L&D clients	161,476



PMTCT_STAT_DSD	By: Known positives at entry	3,187
PMTCT_STAT_DSD	By: Number of new positives identified	5,801
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	8,988
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	412,738
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	47,410
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	86,180
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	38,918
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	240,230
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	86,328
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	326,410
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	412,738
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1,071
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	6,035
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1,010
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	12,398
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	13,998
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	152,485
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	77,784
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	9,715
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	158,756
GEND_GBV_DSD	Number of people receiving post-GBV care	15,245
GEND_GBV_DSD	Age/Sex: <10 Male	1,540
GEND_GBV_DSD	Age/Sex: 10-14 Male	1,875

GEND_GBV_DSD	Age/Sex: 20-24 Male	882
GEND_GBV_DSD	Age/Sex: 25-49 Male	1,142
GEND_GBV_DSD	Age/Sex: 50+ Male	130
GEND_GBV_DSD	Age/Sex: <10 Female	1,673
GEND_GBV_DSD	Age/Sex: 10-14 Female	2,662
GEND_GBV_DSD	Age/Sex: 20-24 Female	1,067
GEND_GBV_DSD	Age/Sex: 25-49 Female	1,359
GEND_GBV_DSD	Age/Sex: 50+ Female	152
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	7,750
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	10,162
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	5,083
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	639
GEND_GBV_DSD	Age/Sex: 15-19 Female	1,405
GEND_GBV_DSD	Age/Sex: 15-19 male	1,358
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	148,241
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	5,162
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	44,164
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	5,325
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	93,590
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	2,296
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,296
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,040
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	231
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	25
PMTCT_EID_DSD	By infants who received a virologic test within 2 months	6,495

	of birth	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	2,051
PMTCT_EID_DSD	Sum of Infant Age disaggregates	8,546
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	196
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	70
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	156,051
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,585
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	45,089
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5,193
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	100,184
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	10,778
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	145,273
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	156,051
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	32,548
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,318
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	9,521
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,416
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	20,293
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	32,548
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	85,195
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	94,512
TX_PVLS_DSD	Numerator: Indication: Routine	29,412
TX_PVLS_DSD	Numerator: Indication: Targeted	55,783



TX_PVLS_DSD	Denominator: Indication: Routine	32,548
TX_PVLS_DSD	Denominator: Indication: Targeted	61,964
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	3,214
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	24,751
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	3,144
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	54,086
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,545
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	27,449
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3,493
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	60,025
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17,247
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	23,074
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	726
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,996
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	813
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,712
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	991
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	6,678



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,110
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,295
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	193
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	190
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	129
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	100
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	72
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	15
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	7
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	70
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	51
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	66



LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	7
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	7
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	2
LAB_PT_TA	CD4: Number of laboratories that perform this testing	2
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	130
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	129
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	130
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	2
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	2

Implementing Mechanism Details

Mechanism ID: 18238	TBD: Yes
REDACTED	

Implementing Mechanism Details



Mechanism ID: 18239	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18243	Mechanism Name: AFENET Follow-On
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	200,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	200,000
Food and Nutrition: Policy, Tools, and Service Delivery	100,000

Budget Code Information

Mechanism ID:	18243		
Mechanism Name:	AFENET Follow-On		
Prime Partner Name:	African Field Epidemiology Network		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	200,000	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	14
HRH_PRE	By Graduates: Laboratory professionals	4
HRH_PRE	By Graduates: Other	10
HRH_PRE	Sum of Graduates disaggregated	14

Implementing Mechanism Details

Mechanism ID: 18258	Mechanism Name: PHII
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Public Health Informatics Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount
GHP-State	150,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18258		
Mechanism Name:	PHII		
Prime Partner Name:	Public Health Informatics Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Agency Information - Costs of Doing Business

U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		63,509		282,491	63,509	346,000
ICASS		189,059		840,941	189,059	1,030,000
Institutional Contractors		806,983		3,589,484	806,983	4,396,467



Management Meetings/Professional Development		86,637		385,363	86,637	472,000
Non-ICASS Administrative Costs		174,742		777,258	174,742	952,000
Staff Program Travel		53,230		236,770	53,230	290,000
USG Staff Salaries and Benefits - Internationally Recruited		480,312		1,554,864	480,312	2,035,176
USG Staff Salaries and Benefits - Locally Recruited		347,813		1,547,078	347,813	1,894,891
Total	0	2,202,285	0	9,214,249	2,202,285	11,416,534

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		38,000		0	38,000	38,000
ICASS		25,459		324,541	25,459	350,000



Institutional Contractors	0	800,000	0	0	800,000	800,000
Management Meetings/Professional Development		15,092		64,908	15,092	80,000
Non-ICASS Administrative Costs		100,000		0	100,000	100,000
Staff Program Travel		125,368		259,632	125,368	385,000
USG Staff Salaries and Benefits - Internationally Recruited		348,021		359,579	348,021	707,600
USG Staff Salaries and Benefits - Locally Recruited		222,898		289,502	222,898	512,400
Total	0	1,674,838	0	1,298,162	1,674,838	2,973,000

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
-------------------------------	-----	-----------	-----------	------------------	-------	---



Capital Security Cost Sharing		185,399		0	185,399	185,399
Computers/IT Services		841,000		0	841,000	841,000
ICASS	411,009	889,511		0	1,300,520	1,300,520
Institutional Contractors	0	2,666,474		0	2,666,474	2,666,474
Management Meetings/Professional Development		30,000		0	30,000	30,000
Non-ICASS Administrative Costs		1,959,500		0	1,959,500	1,959,500
Staff Program Travel	0	879,000		0	879,000	879,000
USG Staff Salaries and Benefits - Internationally Recruited	2,207,741	0		0	2,207,741	2,207,741
USG Staff Salaries and Benefits - Locally Recruited	0	2,977,289		0	2,977,289	2,977,289
Total	2,618,750	10,428,173	0	0	13,046,923	13,046,923

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business
-------------------------------	-----	-----------	-----------	------------------	-------	----------------------------------



						Categories and Applied Pipeline Amount
Capital Security Cost Sharing		20,342		0	20,342	20,342
ICASS		66,049		0	66,049	66,049
Management Meetings/Professional Development		304,038		0	304,038	304,038
Non-ICASS Administrative Costs		144,690		0	144,690	144,690
Staff Program Travel		125,000		0	125,000	125,000
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited		103,650		0	103,650	103,650
Total	0	763,769	0	0	763,769	763,769

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business



						Categories and Applied Pipeline Amount
Computers/IT Services		5,200		0	5,200	5,200
Institutional Contractors				0	0	0
Management Meetings/Professional Development		0		5,390	0	5,390
Non-ICASS Administrative Costs		98,500		47,000	98,500	145,500
Peace Corps Volunteer Costs		1,669,390		422,700	1,669,390	2,092,090
Staff Program Travel		20,700		0	20,700	20,700
USG Staff Salaries and Benefits - Locally Recruited		293,200		0	293,200	293,200
Total	0	2,086,990	0	475,090	2,086,990	2,562,080